Целевое применение гепатопротекторов для лечения различных стадий неалкогольной жировой болезни печени (жировой дегенерации печени по МКБ 10) и ассоциированных коморбидных состояний; таблицы для врачебного пользования

Высокая распространенность НАЖБП, которая коррелирует с метаболическим синдромом, обуславливает необходимость рационального выбора препаратов для коррекции не только стадий стеатоза, стеатогепатита и фиброза печени, но и ее метаболических фенотипов. В оригинальных таблицах наглядно представлены возможности комбинированного применения статинов, фенофибратов, ингибиторов ангиотензинпревращающего фермента, блокаторов рецепторов ангиотензина II, натрийзависимых ингибиторов транспортера глюкозы 2 типа, агонистов рецепторов глюкагоноподобного пептида-1, ресметирома, урсодезоксихолевой и глицеризиновой кислот и их комбинаций, эссенциальных фосфолипидов, адеметионина, орнитина аспартата, таурина, гидролизата плаценты человека, морфолина, силимарина, экстракта листьев артишока, метформина, пиоглитазона и комбинированного раствора янтарной кислоты в зависимости от клинической ситуации. В основу подтверждающего списка литературы положены «Шкалы оценки уровней достоверности доказательств», утвержденные Приказом Министерства здравоохранения Российской Федерации от 28 февраля 2019 г. No 103н «Об утверждении Порядка и сроков разработки клинических рекомендаций, их пересмотра, типовой формы клинических рекомендаций и требований к их структуре», состав и научная обоснованность информации, включенной в клинические рекомендации» (с изменениями и дополнениями).

НАЖБП, метаболический синдром, рациональные комбинации, гепатопротекция, статины, фенофибраты, ингибиторы ангиотензинпревращающего фермента, блокаторы рецепторов ангиотензина II, натрийзависимые ингибиторы транспортера глюкозы 2 типа, агонисты рецепторов глюкагоноподобного пептида-1, ресметиром, урсодезоксихолевая и глицеризиновая кислоти и их комбинации, эссенциальные фосфолипиды, адеметионин, орнитина аспартата, таурин, гидролизат плаценты человека, морфолин, силимарин, экстракт листьев артишока, метформин, пиоглитазон и комбинированный раствор янтарной кислоты

1. Riazi K., Azhari H., Charette J.H. et al. The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2022 Sep;7(9):851-861. doi: 10.1016/S2468-1253(22)00165-0

2. Lee E.J., Choi M., Ahn S.B. et al. Prevalence of nonalcoholic fatty liver disease in pediatrics and adolescents: a systematic review and meta-analysis. World J Pediatr. 2024;20(6):569-580. doi: 10.1007/s12519-024-00814-1.

3. Maev I.V., Andreev D.N., Kucheryavyy Yu.A. Prevalence of non-alcoholic fat disease liver in Russian Federation: meta-analysis. Consilium Medicum. 2023;25(5):313-319. (in Russ.) doi: 10.26442/20751753.2023.5.202155.@@ Маев И.В., Андреев Д.Н., Кучерявый Ю.А. Распространенность неалкогольной жировой болезни печени в России: метаанализ. Consilium Medicum. 2023;25(5):313-319. doi: 10.26442/20751753.2023.5.202155.

4. Paik J.M., Golabi P., Younossi Y., Mishra A., Younossi Z.M. Changes in the Global Burden of Chronic Liver Diseases From 2012 to 2017: The Growing Impact of NAFLD. Hepatology. 2020 Nov;72(5):1605-1616. doi: 10.1002/hep.31173.

5. Estes C., Razavi H., Loomba R., Younossi Z., Sanyal A.J. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. Hepatology. 2018 Jan;67(1):123-133. doi: 10.1002/hep.29466.

6. Pennisi G., Enea M., Romero-Gomez M. et al. Liver-related and extrahepatic events in patients with non-alcoholic fatty liver disease: a retrospective competing risks analysis. Aliment Pharmacol Ther. 2022 Mar;55(5):604-615. doi: 10.1111/apt.16763.

7. Mantovani A., Petracca G., Beatrice G., Tilg H., Byrne C.D., Targher G. Non-alcoholic fatty liver disease and risk of incident diabetes mellitus: an updated meta-analysis of 501 022 adult individuals. Gut. 2021 May;70(5):962-969. doi: 10.1136/gutjnl-2020-322572.

8. Mantovani A., Petracca G., Beatrice G. et al. Non-alcoholic fatty liver disease and risk of incident chronic kidney disease: an updated meta-analysis. Gut. 2022 Jan;71(1):156-162. doi: 10.1136/gutjnl-2020-32308.

9. Mantovani A., Csermely A., Petracca G. et al. Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: an updated systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2021 Nov;6(11):903-913. doi: 10.1016/S2468-1253(21)00308-3.

10. Meyersohn N.M., Mayrhofer T., Corey K.E. et al. Association of Hepatic Steatosis With Major Adverse Cardiovascular Events, Independent of Coronary Artery Disease. Clin Gastroenterol Hepatol. 2021 Jul;19(7):1480-1488.e14. doi: 10.1016/j.cgh.2020.07.030.

11. Mantovani A., Petracca G., Csermely A. et al. Non-alcoholic fatty liver disease and risk of new-onset heart failure: an updated meta-analysis of about 11 million individuals. Gut. 2023;72:372-80.

12. Zannad F., Sanyal A.J., Butler J. et al. MASLD and MASH at the crossroads of hepatology trials and cardiorenal metabolic trials. J Intern Med. 2024 Jul;296(1):24-38. doi: 10.1111/joim.13793.

13. Islam ANMS, Sultana H., Nazmul Hassan Refat M., Farhana Z., Abdulbasah Kamil A., Meshbahur Rahman M. The global burden of overweight-obesity and its association with economic status, benefiting from STEPs survey of WHO member states: A meta-analysis. Prev Med Rep. 2024 Sep 5;46:102882. doi: 10.1016/j.pmedr.2024.102882.

14. Oishi Y., Manabe I. Organ System Crosstalk in Cardiometabolic Disease in the Age of Multimorbidity. Front Cardiovasc Med. 2020 Apr 28;7:64. doi: 10.3389/fcvm.2020.00064.

15. Stahl E.P., Dhindsa D.S., Lee S.K., Sandesara P.B., Chalasani N.P., Sperling L.S. Nonalcoholic Fatty Liver Disease and the Heart: JACC State-of-the-Art Review. J Am Coll Cardiol. 2019 Mar 5;73(8):948-963. doi: 10.1016/j.jacc.2018.11.050.

16. Cheung A., Ahmed A. Nonalcoholic Fatty Liver Disease and Chronic Kidney Disease: A Review of Links and Risks. Clin Exp Gastroenterol. 2021 Nov 17;14:457-465. doi: 10.2147/CEG.S226130.

17. Mantovani A., Byrne C.D., Benfari G., Bonapace S., Simon T.G., Targher G. Risk of Heart Failure in Patients With Nonalcoholic Fatty Liver Disease: JACC Review Topic of the Week. J Am Coll Cardiol. 2022 Jan 18;79(2):180-191. doi: 10.1016/j.jacc.2021.11.007.

18. Lazebnik L.B., Golovanova E.V., Turkina S.V. et al. Non-alcoholic fatty liver disease in adults: clinic, diagnostics, treatment. Guidelines for therapists, third version. Experimental and Clinical Gastroenterology. 2021;1(1):4-52. (In Russ.) doi: 10.31146/1682-8658-ecg-185-1-4-52.@@ Лазебник Л.Б., Голованова Е.В., Туркина С.В. и др. Неалкогольная жировая болезнь печени у взрослых: клиника, диагностика, лечение. Рекомендации для терапевтов, третья версия. Экспериментальная и клиническая гастроэнтерология. 2021;1(1):4-52. doi: 10.31146/1682-8658-ecg-185-1-4-52.

19. Haigh L., Kirk C., El Gendy K., Gallacher J., Errington L., Mathers J.C., Anstee Q.M. The effectiveness and acceptability of Mediterranean diet and calorie restriction in non-alcoholic fatty liver disease (NAFLD): A systematic review and meta-analysis. Clin Nutr. 2022 Sep;41(9):1913-1931. doi: 10.1016/j.clnu.2022.06.037.

20. Koutoukidis D.A., Koshiaris C., Henry J.A. et al. The effect of the magnitude of weight loss on non-alcoholic fatty liver disease: A systematic review and meta-analysis. Metabolism. 2021 Feb;115:154455. doi: 10.1016/j.metabol.2020.154455.

21. Fernández T., Viñuela M., Vidal C., Barrera F. Lifestyle changes in patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis. PLoS One. 2022 Feb 17;17(2): e0263931. doi: 10.1371/journal.pone.0263931.

22. Vilar-Gomez E., Martinez-Perez Y., Calzadilla-Bertot L. et al. Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis. Gastroenterology. 2015 Aug;149(2):367-78.e5; quiz e14-5. doi: 10.1053/j.gastro.2015.04.005.

23. Kim D., Vazquez-Montesino L.M., Li A.A., Cholankeril G., Ahmed A. Inadequate Physical Activity and Sedentary Behavior Are Independent Predictors of Nonalcoholic Fatty Liver Disease. Hepatology. 2020 Nov;72(5):1556-1568. doi: 10.1002/hep.31158.

24. Stine J.G., Long M.T., Corey K.E. et al. American College of Sports Medicine (ACSM) International Multidisciplinary Roundtable report on physical activity and nonalcoholic fatty liver disease. Hepatol Commun. 2023 Mar 30;7(4): e0108. doi: 10.1097/HC9.0000000000000108.

25. Baker C.J., Martinez-Huenchullan S.F., D’Souza M., Xu Y., Li M., Bi Y., Johnson N.A., Twigg S.M. Effect of exercise on hepatic steatosis: Are benefits seen without dietary intervention? A systematic review and meta-analysis. J Diabetes. 2021 Jan;13(1):63-77. doi: 10.1111/1753-0407.13086.

26. Oh S., Tsujimoto T., Kim B. et al. Weight-loss-independent benefits of exercise on liver steatosis and stiffness in Japanese men with NAFLD. JHEP Rep. 2021 Feb 10;3(3):100253. doi: 10.1016/j.jhepr.2021.100253.

27. Sabag A., Barr L., Armour M. et al. The Effect of High-intensity Interval Training vs Moderate-intensity Continuous Training on Liver Fat: A Systematic Review and Meta-Analysis. J Clin Endocrinol Metab. 2022 Feb 17;107(3):862-881. doi: 10.1210/clinem/dgab795.

28. Abdelbasset W.K., Tantawy S.A., Kamel D.M., Alqahtani B.A., Soliman G.S. A randomized controlled trial on the effectiveness of 8-week high-intensity interval exercise on intrahepatic triglycerides, visceral lipids, and health-related quality of life in diabetic obese patients with nonalcoholic fatty liver disease. Medicine (Baltimore). 2019 Mar;98(12): e14918. doi: 10.1097/MD.0000000000014918. Erratum in: Medicine (Baltimore). 2020 Sep 11;99(37): e22388. doi: 10.1097/MD.0000000000022388.

29. Duarte-Rojo A., Ruiz-Margáin A., Montaño-Loza A.J., Macías-Rodríguez R.U., Ferrando A., Kim W.R. Exercise and physical activity for patients with end-stage liver disease: Improving functional status and sarcopenia while on the transplant waiting list. Liver Transpl. 2018 Jan;24(1):122-139. doi: 10.1002/lt.24958.

30. Bae J.C., Suh S., Park S.E. et al. Regular exercise is associated with a reduction in the risk of NAFLD and decreased liver enzymes in individuals with NAFLD independent of obesity in Korean adults. PLoS One. 2012;7(10): e46819. doi: 10.1371/journal.pone.0046819.

31. Kwak M.S., Kim D., Chung G.E., Kim W., Kim Y.J., Yoon J.H. Role of physical activity in nonalcoholic fatty liver disease in terms of visceral obesity and insulin resistance. Liver Int. 2015 Mar;35(3):944-52. doi: 10.1111/liv.12552.

32. Hallsworth K., Fattakhova G., Hollingsworth K.G. et al. Resistance exercise reduces liver fat and its mediators in non-alcoholic fatty liver disease independent of weight loss. Gut. 2011 Sep;60(9):1278-83. doi: 10.1136/gut.2011.242073.

33. Jang D.K., Lee J.S., Lee J.K., Kim Y.H. Independent Association of Physical Activity with Nonalcoholic Fatty Liver Disease and Alanine Aminotransferase Levels. J Clin Med. 2019 Jul 10;8(7):1013. doi: 10.3390/jcm8071013.

34. Clarke S.F., Murphy E.F., O’Sullivan O. et al. Exercise and associated dietary extremes impact on gut microbial diversity. Gut. 2014 Dec;63(12):1913-20. doi: 10.1136/gutjnl-2013-306541.

35. Keating S.E., Adams L.A. Exercise in NAFLD: Just do it. J Hepatol. 2016 Oct;65(4):671-673. doi: 10.1016/j.jhep.2016.06.022.

36. O’Gorman P., Naimimohasses S., Monaghan A. et al. Improvement in histological endpoints of MAFLD following a 12-week aerobic exercise intervention. Aliment Pharmacol Ther. 2020 Oct;52(8):1387-1398. doi: 10.1111/apt.15989.

37. Chen G., Banini B.A., Do A., Gunderson C., Zaman S., Lim J.K. Exercise Does Not Independently Improve Histological Outcomes in Biopsy-Proven Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. Genes (Basel). 2023 Sep 17;14(9):1811. doi: 10.3390/genes14091811.

38. Romero-Gómez M., Zelber-Sagi S., Trenell M. Treatment of NAFLD with diet, physical activity and exercise. J Hepatol. 2017 Oct;67(4):829-846. doi: 10.1016/j.jhep.2017.05.016.

39. Hashida R., Kawaguchi T., Bekki M. et al. Aerobic vs. resistance exercise in non-alcoholic fatty liver disease: A systematic review. J Hepatol. 2017 Jan;66(1):142-152. doi: 10.1016/j.jhep.2016.08.023.

40. Dedov I.I., Shestakova M.V., A. Yu. Mayorov. Algorithms of specialized care for patients with diabetes mellitus, 11th issue. Moscow, 2023, 232 p.(in Russ.)@@ Дедов И.И., Шестакова М.В., А.Ю. Майоров. Алгоритмы специализированной помощи больным сахарным диабетом, Москва, 11 выпуск, 2023, 232 с.

41. Ezhov M.V., Kukharchuk V.V., Sergienko I.V. et al. Disorders of lipid metabolism. Clinical Guidelines 2023.Russian Journal of Cardiology. 2023;28(5):5471. (In Russ.) doi: 10.15829/1560-4071-2023-5471.@@ Ежов М.В., Кухарчук В.В., Сергиенко И.В. и др. Нарушения липидного обмена. Клинические рекомендации 2023. Российский кардиологический журнал. 2023;28(5):5471. doi: 10.15829/1560-4071-2023-5471.

42. Barbarash O.L., Karpov Yu.A., Panov A.V. et al. 2024 Clinical practice guidelines for Stable coronary artery disease.Russian Journal of Cardiology. 2024;29(9):6110. (In Russ.) doi: 10.15829/1560-4071-2024-6110.@@ Барбараш О.Л., Карпов Ю.А., Панов А.В. и др. Стабильная ишемическая болезнь сердца. Клинические рекомендации 2024. Российский кардиологический журнал. 2024;29(9):6110. doi: 10.15829/1560-4071-2024-6110.

43. Galyavich A.S., Tereshchenko S.N., Uskach T.M. et al. 2024 Clinical practice guidelines for Chronic heart failure.Russian Journal of Cardiology. 2024;29(11):6162. (In Russ.) https://doi.org/10.15829/1560-4071-2024-6162. EDN: WKIDLJ.@@ Галявич А.С., Терещенко С.Н., Ускач Т.М. и др. Хроническая сердечная недостаточность. Клинические рекомендации 2024. Российский кардиологический журнал. 2024;29(11):6162. https://doi.org/10.15829/1560-4071-2024-6162. EDN: WKIDLJ.

44. Kobalava Zh.D., Konradi A.O., Nedogoda S.V. et al. 2024 Clinical practice guidelines for Hypertension in adults.Russian Journal of Cardiology. 2024;29(9):6117. (In Russ.) doi: 10.15829/1560-4071-2024-6117.@@ Кобалава Ж.Д., Конради А.О., Недогода С.В. и др. Артериальная гипертензия у взрослых. Клинические рекомендации 2024. Российский кардиологический журнал. 2024;29(9):6117. doi: 10.15829/1560-4071-2024-6117.

45. Meex R.C.R., Watt M.J. Hepatokines: linking nonalcoholic fatty liver disease and insulin resistance. Nat Rev Endocrinol. 2017 Sep;13(9):509-520. doi: 10.1038/nrendo.2017.56.

46. Cusi K., Orsak B., Bril F. et al. Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus: A Randomized Trial. Ann Intern Med. 2016 Sep 6;165(5):305-15. doi: 10.7326/M15-1774.

47. Bril F., Kalavalapalli S., Clark V.C., Lomonaco R., Soldevila-Pico C., Liu I.C., Orsak B., Tio F., Cusi K. Response to Pioglitazone in Patients With Nonalcoholic Steatohepatitis With vs Without Type 2 Diabetes. Clin Gastroenterol Hepatol. 2018 Apr;16(4):558-566.e2. doi: 10.1016/j.cgh.2017.12.001.

48. Ratziu V., Harrison S.A., Francque S., Bedossa P. et al.; GOLDEN-505 Investigator Study Group. Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening. Gastroenterology. 2016 May;150(5):1147-1159.e5. doi: 10.1053/j.gastro.2016.01.038.

49. Gawrieh S., Noureddin M., Loo N. et al. Saroglitazar, a PPAR-α/γ Agonist, for Treatment of NAFLD: A Randomized Controlled Double-Blind Phase 2 Trial. Hepatology. 2021 Oct;74(4):1809-1824. doi: 10.1002/hep.31843.

50. Francque S.M., Bedossa P., Ratziu V. et al.; NATIVE Study Group. A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH. N Engl J Med. 2021 Oct 21;385(17):1547-1558. doi: 10.1056/NEJMoa2036205.

51. Jiang S., Uddin M.J., Yu X. et al. Peroxisomal fitness: A potential protective mechanism of fenofibrate against high fat diet-induced non-alcoholic fatty liver disease in mice. Diabetes Metab J. 2022;46(6):829-842. doi:10.4093/dmj.2021.0274.

52. Kokkorakis M., Boutari C., Hill M.A., Kotsis V., Loomba R., Sanyal A.J., Mantzoros C.S. Resmetirom, the first approved drug for the management of metabolic dysfunction-associated steatohepatitis: Trials, opportunities, and challenges. Metabolism. 2024 May;154:155835. doi: 10.1016/j.metabol.2024.155835.

53. Harrison S.A., Bedossa P., Guy C.D. et al.; MAESTRO-NASH Investigators. A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis. N Engl J Med. 2024 Feb 8;390(6):497-509. doi: 10.1056/NEJMoa2309000.

54. Liao C., Liang X., Zhang X., Li Y. The effects of glp-1 receptor agonists on visceral fat and liver ectopic fat in an adult population with or without diabetes and nonalcoholic fatty liver disease: A systematic review and meta-analysis. PLoS One. 2023;18(8): e0289616. doi:10.1371/journal.pone.0289616.

55. Gu Y., Sun L., Zhang W., Kong T., Zhou R., He Y. et al.Comparative efficacy of 5 sodium-glucose cotransporter protein-2 (sglt-2) inhibitor and 4 glucagon-like peptide-1 (glp-1) receptor agonist drugs in non-alcoholic fatty liver disease: A grade-assessed systematic review and network meta-analysis of randomized controlled trials. Front Pharmacol. 2023;14:1102792. doi:10.3389/fphar.2023.1102792.

56. Gu Y., Sun L., He Y., Yang L., Deng C., Zhou R. et al.Comparative efficacy of glucagon-like peptide 1 (glp-1) receptor agonists, pioglitazone and vitamin e for liver histology among patients with nonalcoholic fatty liver disease: Systematic review and pilot network meta-analysis of randomized controlled trials. Expert Rev Gastroenterol Hepatol. 2023;17(3):273-282. doi: 10.1080/17474124.2023.2172397.

57. Romero-Gómez M., Armstrong M.J., Funuyet-Salas J. et al. Improved health-related quality of life with semaglutide in people with non-alcoholic steatohepatitis: A randomised trial. Aliment Pharmacol Ther. 2023;58(4):395-403. doi:10.1111/apt.17598.

58. Mao T, Zhang C, Yang S, Bi Y, Li M, Yu J. Semaglutide alters gut microbiota and improves nafld in db/db mice. Biochem Biophys Res Commun 2024;710:149882. doi:10.1016/j.bbrc.2024.149882, PMID:38583231.

59. Patel Chavez C, Cusi K, Kadiyala S. The Emerging Role of Glucagon-like Peptide-1 Receptor Agonists for the Management of NAFLD. J Clin Endocrinol Metab. 2022 Jan 1;107(1):29-38. doi: 10.1210/clinem/dgab578.

60. Shankar S.S., Daniels S.J., Robertson D. et al. Safety and Efficacy of Novel Incretin Co-agonist Cotadutide in Biopsy-proven Noncirrhotic MASH With Fibrosis. Clin Gastroenterol Hepatol. 2024 Sep;22(9):1847-1857.e11. doi: 10.1016/j.cgh.2024.04.017.

61. Harrison S.A., Browne S.K., Suschak J.J., Tomah S., Gutierrez J.A., Yang J., Roberts M.S., Harris M.S. Effect of pemvidutide, a GLP-1/glucagon dual receptor agonist, on MASLD: A randomized, double-blind, placebo-controlled study. J Hepatol. 2025 Jan;82(1):7-17. doi: 10.1016/j.jhep.2024.07.006.

62. Sanyal A.J., Bedossa P., Fraessdorf M. et al.; 1404-0043 Trial Investigators. A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis. N Engl J Med. 2024 Jul 25;391(4):311-319. doi: 10.1056/NEJMoa2401755.

63. Xu L., Ota T. Emerging roles of SGLT2 inhibitors in obesity and insulin resistance: Focus on fat browning and macrophage polarization. Adipocyte. 2018;7(2):121-128. doi: 10.1080/21623945.2017.1413516.

64. Raj H., Durgia H., Palui R., Kamalanathan S., Selvarajan S., Kar S.S., Sahoo J. SGLT-2 inhibitors in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus: A systematic review. World J Diabetes. 2019 Feb 15;10(2):114-132. doi: 10.4239/wjd.v10.i2.114.

65. Sumida Y., Yoneda M., Tokushige K., Kawanaka M. et al. Antidiabetic Therapy in the Treatment of Nonalcoholic Steatohepatitis.Int J Mol Sci. 2020 Mar 11;21(6):1907. doi: 10.3390/ijms21061907.

66. Meng Z., Liu X., Li T., Fang T., Cheng Y., Han L., Sun B., Chen L. The SGLT2 inhibitor empagliflozin negatively regulates IL-17/IL-23 axis-mediated inflammatory responses in T2DM with NAFLD via the AMPK/mTOR/autophagy pathway.Int Immunopharmacol. 2021 May;94:107492. doi: 10.1016/j.intimp.2021.107492.

67. Prikhodko V.A., Bezborodkina N.N., Okovityi S.V. Pharmacotherapy for Non-Alcoholic Fatty Liver Disease: Emerging Targets and Drug Candidates. Biomedicines. 2022 Jan 26;10(2):274. doi: 10.3390/biomedicines10020274.

68. Тakahashi H., Kessoku T., Kawanaka M. et al. Ipragliflozin Improves the Hepatic Outcomes of Patients With Diabetes with NAFLD. Hepatol Commun. 2022 Jan;6(1):120-132. doi: 10.1002/hep4.1696.

69. Miyake T., Yoshida S., Furukawa S. et al. Ipragliflozin Ameliorates Liver Damage in Non-alcoholic Fatty Liver Disease. Open Med (Wars). 2018 Sep 14;13:402-409. doi: 10.1515/med-2018-0059.

70. Pokharel A., Kc S., Thapa P., Karki N., Shrestha R., Jaishi B., Paudel M.S. The Effect of Empagliflozin on Liver Fat in Type 2 Diabetes Mellitus Patients With Non-Alcoholic Fatty Liver Disease. Cureus. 2021 Jul 28;13(7): e16687. doi: 10.7759/cureus.16687.

71. Lai L.L., Vethakkan S.R., Nik Mustapha N.R., Mahadeva S., Chan W.K. Empagliflozin for the Treatment of Nonalcoholic Steatohepatitis in Patients with Type 2 Diabetes Mellitus. Dig Dis Sci. 2020 Feb;65(2):623-631. doi: 10.1007/s10620-019-5477-1.

72. Seko Y., Nishikawa T., Umemura A. et al. Efficacy and safety of canagliflozin in type 2 diabetes mellitus patients with biopsy-proven nonalcoholic steatohepatitis classified as stage 1-3 fibrosis. Diabetes Metab Syndr Obes. 2018 Nov 27;11:835-843. doi: 10.2147/DMSO.S184767.

73. Aso Y., Kato K., Sakurai S. et al. Impact of dapagliflozin, an SGLT2 inhibitor, on serum levels of soluble dipeptidyl peptidase-4 in patients with type 2 diabetes and non-alcoholic fatty liver disease.Int J Clin Pract. 2019 May;73(5): e13335. doi: 10.1111/ijcp.13335.

74. Tobita H., Sato S., Miyake T., Ishihara S., Kinoshita Y. Effects of Dapagliflozin on Body Composition and Liver Tests in Patients with Nonalcoholic Steatohepatitis Associated with Type 2 Diabetes Mellitus: A Prospective, Open-label, Uncontrolled Study. Curr Ther Res Clin Exp. 2017 Jul 8;87:13-19. doi: 10.1016/j.curtheres.2017.07.002.

75. Marjot T., Green C.J., Charlton C.A. et al. Sodium-glucose cotransporter 2 inhibition does not reduce hepatic steatosis in overweight, insulin-resistant patients without type 2 diabetes. JGH Open. 2019 Nov 5;4(3):433-440. doi: 10.1002/jgh3.12274.

76. Li T., Chiang J.Y. Bile acid signaling in metabolic disease and drug therapy. Pharmacol Rev. 2014 Oct;66(4):948-83. doi: 10.1124/pr.113.008201.

77. Chávez-Talavera O., Tailleux A., Lefebvre P., Staels B. Bile Acid Control of Metabolism and Inflammation in Obesity, Type 2 Diabetes, Dyslipidemia, and Nonalcoholic Fatty Liver Disease. Gastroenterology. 2017 May;152(7):1679-1694.e3. doi: 10.1053/j.gastro.2017.01.055.

78. Panzitt K., Wagner M. FXR in liver physiology: Multiple faces to regulate liver metabolism. Biochim Biophys Acta Mol Basis Dis. 2021 Jul 1;1867(7):166133. doi: 10.1016/j.bbadis.2021.166133.

79. Makri E., Cholongitas E., Tziomalos K. Emerging role of obeticholic acid in the management of nonalcoholic fatty liver disease. World J Gastroenterol. 2016 Nov 7;22(41):9039-9043. doi: 10.3748/wjg.v22.i41.9039.

80. Thanatharayil Sathian Aishwarya, Nadella Mounika, Gayatri Vishwakarma, Ramu Adela, Effect of obeticholic acid in non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) patients: a systematic review and meta-analysis. RPS Pharmacy and Pharmacology Reports. 2022 September;1(1): rqac001. doi: 10.1093/rpsppr/rqac001.

81. Zhao J., Li B., Zhang K., Zhu Z. The effect and safety of obeticholic acid for patients with nonalcoholic steatohepatitis: A systematic review and meta-analysis of randomized controlled trials. Medicine (Baltimore). 2024 Feb 16;103(7): e37271. doi: 10.1097/MD.0000000000037271.

82. Chianelli D., Rucker P.V., Roland J., Tully D.C., Nelson J., Liu X. et al. Nidufexor (lmb763), a novel fxr modulator for the treatment of nonalcoholic steatohepatitis. J Med Chem. 2020;63(8):3868-3880. doi:10.1021/acs.jmedchem.9b01621.

83. Patel K., Harrison S.A., Elkhashab M. et al. Cilofexor, a Nonsteroidal FXR Agonist, in Patients With Noncirrhotic NASH: A Phase 2 Randomized Controlled Trial. Hepatology. 2020 Jul;72(1):58-71. doi: 10.1002/hep.31205.

84. Nimer N., Choucair I., Wang Z. et al. Bile acids profile, histopathological indices and genetic variants for non-alcoholic fatty liver disease progression. Metabolism. 2021 Mar;116:154457. doi: 10.1016/j.metabol.2020.154457.

85. Feng X., Zhang R., Yang Z., Zhang K., Xing J. Mechanism of Metabolic Dysfunction-associated Steatotic Liver Disease: Important role of lipid metabolism. J Clin Transl Hepatol. 2024 Sep 28;12(9):815-826. doi: 10.14218/JCTH.2024.00019.

86. European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J Hepatol. 2024 Sep;81(3):492-542. doi: 10.1016/j.jhep.2024.04.031.

87. Laurin J., Lindor K.D., Crippin J.S., Gossard A., Gores G.J., Ludwig J., Rakela J., McGill D.B. Ursodeoxycholic acid or clofibrate in the treatment of non-alcohol-induced steatohepatitis: a pilot study. Hepatology. 1996 Jun;23(6):1464-7. doi: 10.1002/hep.510230624.

88. Georgescu E.F., Georgescu M. Therapeutic options in non-alcoholic steatohepatitis (NASH). Are all agents alike? Results of a preliminary study. J Gastrointestin Liver Dis. 2007 Mar;16(1):39-46. PMID: 17410287.

89. Xiang Z., Chen Y.P., Ma K.F., Ye Y.F., Zheng L., Yang Y.D., Li Y.M., Jin X. The role of ursodeoxycholic acid in non-alcoholic steatohepatitis: a systematic review. BMC Gastroenterol. 2013 Sep 23;13:140. doi: 10.1186/1471-230X-13-140.

90. Pavlov C.S., Varganova D.L., Semenistaya M.C., Kuznetsova E.A., Usanova A.A., Svistunov A.A. Ursodeoxycholic Acid: Efficacy and Safety in the Treatment of Nonalcoholic Fatty Liver Disease (Meta-Analysis). Annals of the Russian Academy of Medical Sciences. 2018;73(5):294-305. doi: 10.15690/vramn975.@@ Павлов Ч.С., Варганова Д.Л., Семенистая М.Ч., Кузнецова Е.А., Усанова А.А., Свистунов А.А. Урсодезоксихолевая кислота: эффективность и безопасность в лечении неалкогольной жировой болезни печени (метаанализ). Вестник РАМН. 2018;73(5):294-305. doi: 10.15690/vramn975.

91. Pirogova I. Yu., Yakovleva S.V., Neujmina T.V. et al. Pleiotropic effects of Ursosan in non-alcoholic fatty liver disease and metabolic syndrome. Gastroenterology (Suppl. Consilium Medicum). 2018; 1: 7-14. (in Russ.) doi: 10.26442/2414-3529_2018.1.7-14.@@ Пирогова И.Ю., Яковлева С.В., Неуймина Т.В. и др. Влияние препарата Урсосан на стеатоз и фиброз печени, а также показатели метаболического синдрома у больных с неалкогольной жировой болезнью печени: сравнительное исследование «СФЕРА» Consilium medicum. Гастроэнтерология. 2018; 1: 7-14. doi: 10.26442/2414-3529_2018.1.7-14.

92. Mayevskaya M.V., Nadinskaia M. Yu., Lunkov V.D., Pirogova I.Yu., Chesnokov E.V., Kodzoeva Kh.B., Ivashkin V.T. An Effect of Ursodeoxycholic Acid on Inflammation, Steatosis and Liver Fibrosis and Atherogenesis Factors in Patients with Non-Alcoholic Fatty Liver Disease: Results of the USPEH Study.Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2019;29(6):22-29. (In Russ.) doi: 10.22416/1382-4376-2019-29-6-22-29.@@ Маевская М.В., Надинская М.Ю., Луньков В.Д., Пирогова И.Ю., Чесноков Е.В., Кодзоева Х.Б., Ивашкин В.Т. Влияние урсодезоксихолевой кислоты на воспаление, стеатоз и фиброз печени и факторы атерогенеза у больных неалкогольной жировой болезнью печени: результаты исследования УСПЕХ. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2019;29(6):22-29. doi: 10.22416/1382-4376-2019-29-6-22-29.

93. Pirogova I. Yu., Yakovleva S.V., Neuimina T.V. et al. Pleiotropic effects of ursodeoxycholic acid in non-alcoholic fatty liver disease and metabolic syndrome. Consilium Medicum. 2019; 21 (8): 65-70. (in Russ.) doi: 10.26442/20751753.2019.8.190365.@@ Пирогова И.Ю., Яковлева С.В., Неуймина Т.В. и др. Плейотропные эффекты урсодезоксихолевой кислоты при неалкогольной жировой болезни печени и метаболическом синдроме. Consilium Medicum. 2019; 21 (8): 65-70. doi: 10.26442/20751753.2019.8.190365.

94. Wu P., Zhao J., Guo Y., Yu Y., Wu X., Xiao H. Ursodeoxycholic acid alleviates nonalcoholic fatty liver disease by inhibiting apoptosis and improving autophagy via activating AMPK. Biochem Biophys Res Commun. 2020 Aug 27;529(3):834-838. doi: 10.1016/j.bbrc.2020.05.128.

95. Zhang W., Tang Y., Huang J., Hu H. Efficacy of ursodeoxycholic acid in nonalcoholic fatty liver disease: An updated meta-analysis of randomized controlled trials. Asia Pac J Clin Nutr. 2020;29(4):696-705. doi: 10.6133/apjcn.202012_29(4).0004.

96. Lin X., Mai M., He T., Huang H., Zhang P., Xia E., Guo H. Efficiency of ursodeoxycholic acid for the treatment of nonalcoholic steatohepatitis: A systematic review and meta-analysis. Expert Rev Gastroenterol Hepatol. 2022 Jun;16(6):537-545. doi: 10.1080/17474124.2022.2083605.

97. Patel V.S., Mahmood S.F., Bhatt K.H. et al. Ursodeoxycholic Acid’s Effectiveness in the Management of Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-analysis. Euroasian J Hepatogastroenterol. 2024 Jan-Jun;14(1):92-98. doi: 10.5005/jp-journals-10018-1434.

98. Dajani A.I., Popovic B. Essential phospholipids for nonalcoholic fatty liver disease associated with metabolic syndrome: A systematic review and network meta-analysis. World J Clin Cases. 2020 Nov 6;8(21):5235-5249. doi: 10.12998/wjcc.v8.i21.5235.

99. Gonciarz Z., Besser P., Lelek E., Gundermann K.J., Johannes K.J. Randomised placebo-controlled double blind trial on “essential” phospholipids in the treatment of fatty liver associated with diabetes. Méd Chir Dig. 1988;17(1):61-65.

100. Li J.H., Chen X.Y., Zhong C.F., Min J. A randomized controlled study of essential phospholipids (Essentiale capsules) in the treatment of fatty liver. Infect Dis Info. 2000;13(4):180-181.

101. Yin D., Kong L. Observation for curative effect of Essentiale in treatment of fatty liver caused by diabetes mellitus. Med J Q Ilu. 2000;15:277-278.

102. Sun C., Zheng X., Tan Z., Cui F., Zhang R., Zhang H. Clinical observation on polyene phosphatidyl choline and metformin in the treatment of type 2 diabetes and non-alcoholic fatty liver disease. Clin Focus. 2008;23(17):1272-1273.

103. Wu Yan. Efficacy analysis of polyene phosphatidylcholine for type 2 diabetes complicated with fatty liver. Journal of TCM University of Hunan. 2009, 29(12): 41-42.

104. Sas E., Grinevich V., Efimov O., Shcherbina N. Beneficial influence of polyunsaturated phosphatidylcholine enhances functional liver condition and liver structure in patients with nonalcoholic steatohepatitis accompanied by diabetes type 2. Results of prolonged randomized blinded prospective clinical study [abstract]. J Hepatol. 2013;58: S549.

105. Li Zhiguo et al, Efficacy of polyene phosphatidylcholine in combination with metformin for diabetes complicated with non-alcoholic fatty liver disease. Inner Mongol Journal of Traditional Chinese Medicine. 2013, No. 31, 10-11.

106. Maev I.V., Samsonov A.A., Palgova L.K. et al. Effectiveness of phosphatidylcholine in alleviating steatosis in patients with non-alcoholic fatty liver disease and cardiometabolic comorbidities (MANPOWER study). BMJ Open Gastroenterology. 2020;7: e000341.

107. Abuhammour A. Agents for the treatment of fatty liver disease: focus on essential phospholipids. Drugs Ther Perspect. 2021;37:249-264. doi: 10.1007/s40267-021-00838-x

108. NAN Jun, Clinical Analysis of Essentiale Treatment of 90 Patients with Non-alcoholic Fatty Liver, Guide of China Medicine, Vol. 9, No.35 Dec 2009, 249-250.

109. ZHOU Shu-Yun, SUN Zhe-Ying. Observation of Efficacy of Polyene Phosphatidylcholine in the Treatment of Fatty Liver. J Clini Hepatol. June 2010, Vol.26, No.3.

110. Yi Pan et al. Clinical features and real-world treatment patterns of MAFLD patients in China. Hepatol Int. 2024;18(S555): P-0318.

111. Ivashkin V.T., Bakulin I.G., Bogomolov P.O. et al. Efficacy and safety of glycyrrhizic acid combined to essential phospholipids (Phosphogliv) at non-alcoholic fatty liver disease: results of multicenter double blind randomized placebo-controlled post-registration clinical study (IV phase) «Gepard» (PHG-M2/P02-12). Ross z gastroenterol gepatol koloproktol. 2017; 27(2):34-43. (in Russ.)@@ Ивашкин В.Т., Бакулин И.Г., Богомолов П.О. и др. Результаты многоцентрового двойного слепого рандомизированного плацебо контролируемого пострегистрационного (IV фаза) клинического исследования «Гепард» (PHG-M2/P02-12), проведенного с целью оценки эффективности и безопасности комбинированного препарата глицирризиновой кислоты и эссенциальных фосфолипидов (Фосфоглив) при неалкогольной жировой болезни печени. РЖГГК. 2017; 27 (2): 34-43.

112. Butterworth R.F., Canbay A. Hepatoprotection by L-Ornithine L-Aspartate in Non-Alcoholic Fatty Liver Disease. Dig Dis. 2019;37(1):63-68. doi: 10.1159/000491429.

113. Garanina Е.V. Effect of L-Ornithine-L-Aspartate on Liver Fibrosis and Steatosis in Patients with Metabolic-Asso - ciated Fatty Liver Disease (Non-alcoholic Fatty Liver Disease) and Hyperammonaemia.Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2021;31(4):31-36. (In Russ.) doi: 10.22416/1382-4376-2021-31-4-31-36.@@ Гаранина Е.В. Влияние курсового приема L-орнитин-L-аспартата на фиброз и стеатоз печени у больных ассоциированной с нарушениями метаболизма жировой болезнью печени (неалкогольной жировой болезнью печени), имеющих гипераммониемию. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2021;31(4):31-36. doi: 10.22416/1382-4376-2021-31-4-31-36.

114. Grüngreiff K., Lambert-Baumann J., Med. Welt. 2001; 52: 219-222.

115. Petrova E. M., Cheraneva V.A., Grachev V.G. Hepatogenic weakness as a clinical marker of hyperammonemia and of the effectiveness of its correction in patients with pre-cirrhotic stages of non-alcoholic fatty liver disease. Lvrach.ru. 2020; 8:48-53. (in Russ.)@@ Петрова Э.М., Черанева В.А., Грачев В.Г. Гепатогенная слабость как клинический маркер гипераммониемии и эффективность ее коррекции у пациентов с доцирротическими стадиями неалкогольной жировой болезни печени Лечащий врач. 2020; 8:48-53.

116. Ermolova T., Ermolov S. Correction of intrahepatic microcirculation disorders by L-ornithine L-aspartate in chronic liver disease patients. J Hepatol. 2018;68(Sup-pl 1): S585-6

117. Zvenigorodskaia L.A., Ovsiannikova O.N., Noskova K.K. et al. [Taurine in the treatment of non-alcoholic fatty liver disease]. Eksp. klin. gastroenterol. 2010;(7): 43-50. (in Russ.)@@ Звенигородская Л.А., Овсянникова О.Н., Носкова К.К. и др. Таурин в лечении неалкогольной жировой болезни печени. Эксперим. и клин. гастроэнтерология. 2010; 7: 43-50.

118. Zvenigorodskaia L.A., Nilova T.V. [Taurine in the treatment of non-alcoholic fatty liver disease]. Eksp. klin. gastroenterol. 2012; 11: 70-4. (in Russ.)@@ Звенигородская Л.А., Нилова Т.В. Таурин в лечении неалкогольной жировой болезни печени. Эксперим. и клин. гастроэнтерология. 2012; 11: 70-4.

119. Ovsiannikova O.N., Zvenigorodskaia L.A. [The feasibility of using taurine in the treatment of non-alcoholic fatty liver disease]. Effektivnaia farmakoterapiia. 2012; 24: 38-43. (in Russ.)@@ Овсянникова О.Н., Звенигородская Л.А. Целесообразность применения таурина в лечении неалкогольной жировой болезни печени. Эффективная фармакотерапия. 2012; 24: 38-43. /

120. Zvenigorodskaya L. A., Nilova T.V. [Taurine in the treatment of non-alcoholic fatty liver disease]. Eksp Klin Gastroenterol. 2013; 11: 70-74. (in Russ.)@@ Звенигородская Л.А., Нилова Т.В. Таурин в лечении неалкогольной жировой болезни печени. Экспериментальная и клиническая гастроэнтерология. 2013; 11: 70-74.

121. Murakami S., Ono A., Kawasaki A., Takenaga T., Ito T. Taurine attenuates the development of hepatic steatosis through the inhibition of oxidative stress in a model of nonalcoholic fatty liver disease in vivo and in vitro. Amino Acids. 2018;50(9):1279-1288. doi: 10.1007/s00726-018-2605-8.

122. Obinata K., Maruyama T., Hayashi M., Watanabe T., Nittono H. Effect of taurine on the fatty liver of children with simple obesity. Adv Exp Med Biol. 1996;403:607-613. doi: 10.1016/j.jcjd.2020.05.004.

123. Statsenko M.E., Turkina S.V., Shilina N.N. et al. Nonalcoholic fatty liver disease pharmacotherapy: accent on fibrosis. Consilium Medicum. 2018;20 (8): 37-41. doi: 10.26442/2075-1753_2018.8.37-41.@@ Стаценко М.Е., Туркина С.В., Шилина Н.Н. и др. Фармакотерапия неалкогольной жировой болезни печени: акцент на фиброз. Consilium Medicum. 2018; 20 (8): 37-41. doi: 10.26442/2075-1753_2018.8.37-41.

124. Lazebnik L.B., Golovanova E.V., Simanenkov V.I. et al. Possibilities of polytropic therapy with thiotriazoline in patients with non-alcoholic steatohepatosis and cardiovascular risk factors. The results of the TRIGON-1 observation program. Experimental and Clinical Gastroenterology. 2020;(8):10-18. (In Russ.) doi: 10.31146/1682-8658-ecg-180-8-10-18.@@ Лазебник Л.Б., Голованова Е.В., Симаненков В.И. и др. Возможности политропной терапии тиотриазолином у пациентов с неалкогольным стеатогепатозом и сердечно-сосудистыми факторами риска. Результаты наблюдательной программы «ТРИГОН -1». Экспериментальная и клиническая гастроэнтерология. 2020;180(8):10-18. doi: 10.31146/1682-8658-ecg-180-8-10-18.

125. Polukhina A.V., Vinnitskaya E.V., Bordin D.S., Sandler Yu.G. Non-alcoholic fatty liver disease in comorbid patients: experience of therapy using Thiotriazoline. Effective pharmacotherapy. 2018, No. 3. (in Russ.)@@ Полухина А.В., Винницкая Е.В., Бордин Д.С., Сандлер Ю.Г. Неалкогольная жировая болезнь печени у коморбидных пациентов: опыт терапии с использованием Тиотриазолина. Эффективная фармакотерапия, 2018, № 3.

126. Sandler Yu.G., Matveeva Yu.A., Vinnitskaya E.V., Gendrikson L.N., Keyan V.A. Possibilities of using antihypoxic and antioxidant therapy in non-alcoholic liver disease. RMJ. 2016, No. 22, pp. 1-4. (in Russ.)@@ Сандлер Ю.Г., Матвеева Ю.А., Винницкая Е.В., Гендриксон Л.Н., Кейян В.А. Возможности применения антигипоксантной и антиоксидантной терапии при неалкогольной болезни печени. РМЖ, 2016 № 22.-С.1-4.

127. Federico A., Dallio M., Loguercio C. Silymarin/Silybin and Chronic Liver Disease: A Marriage of Many Years. Molecules. 2017 Jan 24;22(2):191. doi: 10.3390/molecules22020191.

128. Hashemi S.J. A placebocotrolled trial of silymarin in patients with non-alcoholic liver disease. Hepat.Mon. 2009; 9(4): 265-270.

129. Wah Kheong C., Nik Mustapha N.R., Mahadeva S. A Randomized Trial of Silymarin for the Treatment of Nonalcoholic Steatohepatitis. Clin Gastroenterol Hepatol. 2017 Dec;15(12):1940-1949.e8. doi: 10.1016/j.cgh.2017.04.016.

130. Lazebnik L.B., Radchenko V.G., Dzhadhav S.N., Sitkin S.I., Seliverstov P.V. Systemic inflammation and non-alcoholic fatty liver disease. Experimental and Clinical Gastroenterology. 2019;(5):29-41. (In Russ.) doi: 10.31146/1682-8658-ecg-165-5-29-41.@@ Лазебник Л.Б., Радченко В.Г., Джадхав С.Н., Ситкин С.И., Селиверстов П.В. Системное воспаление и неалкогольная жировая болезнь печени. Экспериментальная и клиническая гастроэнтерология. 2019;165(5): 29-41. doi: 10.31146/1682-8658-ecg-165-5-29-41.

131. Pirogova I. Yu., Neuimina T.V., Suchkova O.V., Flegontova M.N., Gogoleva S.P., Gulyants N.M., Sorokina V.K. Laennec (Human placenta hydrolyzate) in monotherapy of mixed etiology of steatohepatitis. Experimental and Clinical Gastroenterology. 2023;(8):37-47. (In Russ.) doi: 10.31146/1682-8658-ecg-216-8-37-47.@@ Пирогова И.Ю., Неуймина Т.В., Сучкова О.В., Флегонтова М.Н., Гоголева С.П., Гульянц Н.М., Сорокина В.К. Препарат Лаеннек (гидролизат плаценты человека) в монотерапии стеатогепатитов смешанной этиологии. Экспериментальная и клиническая гастроэнтерология. 2023;(8):37-47. doi: 10.31146/1682-8658-ecg-216-8-37-47.

132. Imawari M., Nagase M., Torshin I. Yu., Gromova O.A. An open-label, controlled trial of the clinical effects of Laennec® in patients with nonalcoholic steatohepatitis or cirrhosis. FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology. 2023;16(3):447-455. (In Russ.) doi: 10.17749/2070-4909/farmakoekonomika.2023.206.@@ Имавари М., Нагасе М., Торшин И.Ю., Громова О.А. Открытое контролируемое исследование клинических эффектов препарата Лаеннек® у пациентов с неалкогольным стеатогепатитом или циррозом печени. Современная фармакоэкономика и фармакоэпидемиология. 2023;16(3):447-455. doi: 10.17749/2070-4909/farmakoekonomika.2023.206.

133. Baranovsky A. Yu., Raykhelson K.L., Marchenko N.V. Application of S-adenosylmethionine (Heptral®) in treatment of patients with non-alcoholic steatohepatitis. Klinicheskie Perspektivy Gastroenterologii, Gepatologii = Clin Perspect Gastroenterol Hepatol. 2010;9(1):3-10. (In Russ.)@@ Барановский А.Ю., Райхельсон К.Л., Марченко Н.В. Применение S-аденозилметионина (Гептрала®) в терапии больных неалкогольным стеатогепатитом. Клинические перспективы гастроэнтерологии, гепатологии. 2010;9(1):3-10.

134. Korochanskaya N.V., Durleshter V.M., Bacenko M.A. S-ademetionine in the treatment of non-alcoholic fatty liver disease (NAFLD). Experimental and Clinical Gastroenterology. 2021;(7):68-73. (In Russ.) doi: 10.31146/1682-8658-ecg-191-7-68-73.@@ Корочанская Н.В., Дурлештер В.М., Баценко М.А. S-адеметионин в лечении неалкогольной жировой болезни печени (НАЖБП). Экспериментальная и клиническая гастроэнтерология. 2021;(7):68-73. doi: 10.31146/1682-8658-ecg-191-7-68-73.

135. Saigal S., Kapoor D., Roy D.S. Ademetionine in patients with liver disease: a reweviw.Int J Res Med Sci. 2019;7(6):2482-93.

136. Noureddin M., Sander-Struckmeier S., Mato J.M. Early treatment efficacy of S-adenosylmethionine in patients with intrahepatic cholestasis: A systematic review. World J Hepatol. 2020 Feb 27;12(2):46-63. doi: 10.4254/wjh.v12.i2.46.

137. Seliverstov P., Sitkin S., Radchenko V. et al.Combined lipid-lowering therapy in patients with nonalcoholic fatty liver disease. Vrach. 2018; 29 (11):36-43. (in Russ.) doi: 10.29296/25877305-2018-11-07.@@ Селиверстов П., Ситкин С., Радченко В. и др. Комбинированная гиполипидемическая терапия у пациентов с неалкогольной жировой болезнью печени. Врач. - 2018; 29 (11): 36-43. doi: 10.29296/25877305-2018-11-07.

138. Rangboo V., Noroozi M. et al. The Effect of Artichoke Leaf Extract on ALT and AST in THE Patients with NASHnt.International Journal of Hepatology. 2016, ArticleID. 4030476. 4.

139. Kamel A.M., Farag M.A. Therapeutic Potential of Artichoke in the Treatment of Fatty Liver: A Systematic Review and Meta-Analysis. J Med Food. 2022 Oct;25(10):931-942. doi: 10.1089/jmf.2022.0025.

140. Semiserin V.A., Karakozov A.G., Malkuta M.A. et al. Evaluation of the efficiency of hepatoprotective monotherapy using succinic acid and methionine for nonalcoholic fatty liver disease at the stage of steatohepatitis. Terapevticheskii arkhiv. 2016;88(2):58-63. (in Russ.) doi: 10.17116/terarkh201688258-63.@@ Семисёрин В.А., Каракозов А.Г., Малькута М.А., Золотарёва Л.А., Левченко О.Б., Калягин И.Е., Еремин М.Н. Оценка эффективности гепатопротективной монотерапии неалкогольной жировой болезни печени в стадии стеатогепатита препаратом на основе янтарной кислоты и метионина. Терапевтический архив. 2016;88(2):58-63. doi: 10.17116/terarkh201688258-63.

141. Varlamova N.N., Zinov’eva E.N., Teslya O.V., Sinel’nikova E.V., Chasnyk V.G. Assessment of effectiveness of remaxol in patients with nonalcoholic fatty liver disease. Diagnostic radiology and radiotherapy. 2017;(4):33-37. (In Russ.) doi: 10.22328/2079-5343-2017-4-33-37.@@ Варламова Н.Н., Зиновьева Е.Н., Тесля О.В., Синельникова Е.В., Часнык В.Г. Оценка эффективности ремаксола у пациентов с неалкогольной жировой болезнью печени. Лучевая диагностика и терапия. 2017;(4):33-37. doi: 10.22328/2079-5343-2017-4-33-37.

142. Rinella M.E., Neuschwander-Tetri B.A., Siddiqui M.S., Abdelmalek M.F., Caldwell S., Barb D. et al. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023;77(5):1797-1835. doi: 10.1097/HEP.0000000000000323.

143. European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016;64(6):1388-1402. doi: 10.1016/j.jhep.2015.11.004.

144. Chalasani N., Younossi Z., Lavine J.E. et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67(1):328-357. doi: 10.1002/hep.29367.

145. Ando Y., Jou J.H. Nonalcoholic Fatty Liver Disease and Recent Guideline Updates. Clin Liver Dis (Hoboken). 2021;17(1):23-28. doi: 10.1002/cld.1045.

146. Karedath J., Javed H., Ahsan Talpur F. et al. Effect of Vitamin E on Clinical Outcomes in Patients With Non-alcoholic Fatty Liver Disease: A Meta-Analysis. Cureus. 2022;14(12): e32764. doi: 10.7759/cureus.32764.

147. Xu R., Tao A., Zhang S., Deng Y., Chen G. Association between vitamin E and non-alcoholic steatohepatitis: a meta-analysis.Int J Clin Exp Med. 2015;8(3):3924-3934.

148. Mazhar I.J., Yasir M., Sarfraz S. et al. Vitamin E and Pioglitazone: A Comprehensive Systematic Review of Their Efficacy in Non-alcoholic Fatty Liver Disease. Cureus. 2023;15(8): e43635. doi: 10.7759/cureus.43635.

149. Mach F., Baigent C., Catapano A.L. et al. 2019 ESC/EAS Guidelines for themanagement of dyslipidaemias: lipid modification to reduce cardiovascular risk.Russian Journal of Cardiology. 2020;25(5):3826. (In Russ.) doi: 10.15829/1560-4071-2020-3826.@@ Mach F., Baigent C., Catapano A.L., и др. 2019 Рекомендации ESC/EAS по лечению дислипидемий: модификация липидов для снижения сердечно-сосудистого риска. Российский кардиологический журнал. 2020;25(5):3826. doi: 10.15829/1560-4071-2020-3826.

150. Grundy S.M., Stone N.J., Bailey A.L. et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019 Jun 25;73(24):3168-3209. doi: 10.1016/j.jacc.2018.11.002.

151. Grundy S.M., Stone N.J., Bailey A.L. et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019 Jun 25;73(24):3168-3209. doi: 10.1016/j.jacc.2018.11.002. Epub 2018 Nov 10. Erratum in: J Am Coll Cardiol. 2019 Jun 25;73(24):3237-3241. doi: 10.1016/j.jacc.2019.05.013

152. Eslam M., Sarin S.K., Wong V.W. et al. The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease. Hepatol Int. 2020 Dec;14(6):889-919. doi: 10.1007/s12072-020-10094-2.

153. Zhou H., Toshiyoshi M., Zhao W., Zhao Y., Zhao Y. Statins on nonalcoholic fatty liver disease: A systematic review and meta-analysis of 14 RCTs. Medicine (Baltimore). 2023;102(26): e33981. doi: 10.1097/MD.0000000000033981.

154. Pastori D., Pani A., Di Rocco A., Menichelli D., Gazzaniga G., Farcomeni A. et al. Statin liver safety in non-alcoholic fatty liver disease: A systematic review and metanalysis. Br J Clin Pharmacol. 2022;88(2):441-451. doi: 10.1111/bcp.14943.

155. Abdallah M., Brown L., Provenza J., Tariq R., Gowda S., Singal A.K. Safety and efficacy of dyslipidemia treatment in NAFLD patients: a meta-analysis of randomized controlled trials. Ann Hepatol. 2022;27(6):100738. doi: 10.1016/j.aohep.2022.100738.

156. Athyros V.G., Boutari C., Stavropoulos K., Anagnostis P., Imprialos K.P., Doumas M., Karagiannis A. Statins: An Under-Appreciated Asset for the Prevention and the Treatment of NAFLD or NASH and the Related Cardiovascular Risk. Curr Vasc Pharmacol. 2018;16(3):246-253. doi: 10.2174/1570161115666170621082910.

157. Torres-Peña J.D., Martín-Piedra L., Fuentes-Jiménez F. Statins in Non-alcoholic Steatohepatitis. Front Cardiovasc Med. 2021;8:777131. doi: 10.3389/fcvm.2021.777131.

158. Fatima K., Moeed A., Waqar E., Atif A.R. et al. Efficacy of statins in treatment and development of non-alcoholic fatty liver disease and steatohepatitis: A systematic review and meta-analysis. Clin Res Hepatol Gastroenterol. 2022 Apr;46(4):101816. doi: 10.1016/j.clinre.2021.101816.

159. Fernández-Miranda C., Pérez-Carreras M., Colina F., López-Alonso G., Vargas C., Solís-Herruzo J.A. A pilot trial of fenofibrate for the treatment of non-alcoholic fatty liver disease. Dig Liver Dis. 2008;40(3):200-205. doi: 10.1016/j.dld.2007.10.002.

160. Mahmoudi A., Moallem S.A., Johnston T.P., Sahebkar A. Liver Protective Effect of Fenofibrate in NASH/NAFLD Animal Models. PPAR Res. 2022:5805398. doi: 10.1155/2022/5805398.

161. Lawitz E.J., Bhandari B.R., Ruane P.J. et al. Fenofibrate Mitigates Hypertriglyceridemia in Nonalcoholic Steatohepatitis Patients Treated With Cilofexor/Firsocostat. Clin Gastroenterol Hepatol. 2023;21(1):143-152.e3. doi: 10.1016/j.cgh.2021.12.044.

162. Georgescu E.F., Ionescu R., Niculescu M., Mogoanta L., Vancica L. Angiotensin-receptor blockers as therapy for mild-to-moderate hypertension-associated non-alcoholic steatohepatitis. World J Gastroenterol. 2009 Feb 28;15(8):942-54. doi: 10.3748/wjg.15.942.

163. Orlic L., Mikolasevic I., Lukenda V. et al. Nonalcoholic fatty liver disease and the renin-angiotensin system blockers in the patients with chronic kidney disease. Wien Klin Wochenschr. 2015;127(9-10):355-62. doi: 10.1007/s00508-014-0661-y.

164. Pelusi S., Petta S., Rosso C. et al. Renin-Angiotensin System Inhibitors, Type 2 Diabetes and Fibrosis Progression: An Observational Study in Patients with Nonalcoholic Fatty Liver Disease. PLoS One. 2016 Sep 20;11(9): e0163069. doi: 10.1371/journal.pone.0163069.

165. Hirata T., Tomita K., Kawai T. et al. Effect of Telmisartan or Losartan for Treatment of Nonalcoholic Fatty Liver Disease: Fatty Liver Protection Trial by Telmisartan or Losartan Study (FANTASY).Int J Endocrinol. 2013:587140. doi: 10.1155/2013/587140.

166. Yokohama S., Yoneda M., Haneda M. et al. Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis. Hepatology. 2004;40(5):1222-1225. doi: 10.1002/hep.20420.

167. Osterreicher C.H., Taura K., De Minicis S. et al. Angiotensin-converting-enzyme 2 inhibits liver fibrosis in mice. Hepatology. 2009;50(3):929-938. doi: 10.1002/hep.23104.

168. Kim G., Kim J., Lim Y.L., Kim M.Y., Baik S.K. Renin-angiotensin system inhibitors and fibrosis in chronic liver disease: a systematic review. Hepatol Int. 2016 Sep;10(5):819-28. doi: 10.1007/s12072-016-9705-x.

169. Zhang X., Wong G.L., Yip T.C. et al. Angiotensin-converting enzyme inhibitors prevent liver-related events in nonalcoholic fatty liver disease. Hepatology. 2022;76(2):469-482. doi: 10.1002/hep.32294.

170. Wei Q., Xu X., Guo L., Li J., Li L. Effect of SGLT2 Inhibitors on Type 2 Diabetes Mellitus With Non-Alcoholic Fatty Liver Disease: A Meta-Analysis of Randomized Controlled Trials. Front Endocrinol (Lausanne). 2021;12:635556. doi: 10.3389/fendo.2021.635556.

171. Mo M., Huang Z., Liang Y., Liao Y., Xia N. The safety and efficacy evaluation of sodium-glucose co-transporter 2 inhibitors for patients with non-alcoholic fatty liver disease: An updated meta-analysis. Dig Liver Dis. 2022;54(4):461-468. doi: 10.1016/j.dld.2021.08.017.

172. Zelniker T.A., Wiviott S.D., Raz I. et al.Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus. Circulation. 2019 Apr 23;139(17):2022-2031. doi: 10.1161/CIRCULATIONAHA.118.038868.

173. Zelniker T.A., Braunwald E. Clinical Benefit of Cardiorenal Effects of Sodium-Glucose Cotransporter 2 Inhibitors: JACC State-of-the-Art Review. J Am Coll Cardiol. 2020 Feb 4;75(4):435-447. doi: 10.1016/j.jacc.2019.11.036.

174. Zelniker T.A., Braunwald E. Mechanisms of Cardiorenal Effects of Sodium-Glucose Cotransporter 2 Inhibitors: JACC State-of-the-Art Review. J Am Coll Cardiol. 2020 Feb 4;75(4):422-434. doi: 10.1016/j.jacc.2019.11.031.

175. Apperloo E.M., Neuen B.L., Fletcher R.A. et al. Efficacy and safety of SGLT2 inhibitors with and without glucagon-like peptide 1 receptor agonists: a SMART-C collaborative meta-analysis of randomised controlled trials. Lancet Diabetes Endocrinol. 2024 Aug;12(8):545-557. doi: 10.1016/S2213-8587(24)00155-4.

176. Sarafidis P., Ferro C.J., Morales E. et al. SGLT-2 inhibitors and GLP-1 receptor agonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. A consensus statement by the EURECA-m and the DIABESITY working groups of the ERA-EDTA. Nephrol Dial Transplant. 2019;34(2):208-230. doi: 10.1093/ndt/gfy407.

177. Musso G., Cassader M., Cohney S., De Michieli F., Pinach S., Saba F., Gambino R. Fatty Liver and Chronic Kidney Disease: Novel Mechanistic Insights and Therapeutic Opportunities. Diabetes Care. 2016;39(10):1830-1845. doi: 10.2337/dc15-1182.

178. Heerspink H.J.L., Stefánsson B.V., Correa-Rotter R. et al. Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2020;383(15):1436-1446. doi: 10.1056/NEJMoa2024816.

179. Herrington W.G., Staplin N., Wanner C. et al. Empagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2023;388(2):117-127. doi: 10.1056/NEJMoa2204233.

180. Perkovic V., Jardine M.J., Neal B., Bompoint S., Heerspink H.J.L., Charytan D.M., Edwards R., Agarwal R., Bakris G., Bull S., Cannon C.P., Capuano G., Chu P.L., de Zeeuw D., Greene T., Levin A., Pollock C., Wheeler D.C., Yavin Y., Zhang H., Zinman B., Meininger G., Brenner B.M., Mahaffey K.W.; CREDENCE Trial Investigators. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. N Engl J Med. 2019 Jun 13;380(24):2295-2306. doi: 10.1056/NEJMoa1811744.

181. Bhatt D.L., Szarek M., Pitt B., Cannon C.P., Leiter L.A., McGuire D.K., Lewis J.B., Riddle M.C., Inzucchi S.E., Kosiborod M.N., Cherney D.Z.I., Dwyer J.P., Scirica B.M., Bailey C.J., Díaz R., Ray K.K., Udell J.A., Lopes R.D., Lapuerta P., Steg P.G.; SCORED Investigators. Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease. N Engl J Med. 2021 Jan 14;384(2):129-139. doi: 10.1056/NEJMoa2030186.

182. Heerspink H.J.L., Stefánsson B.V., Correa-Rotter R., Chertow G.M., Greene T., Hou F.F., Mann J.F.E., McMurray J.J.V., Lindberg M., Rossing P., Sjöström C.D., Toto R.D., Langkilde A.M., Wheeler D.C.; DAPA-CKD Trial Committees and Investigators. Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2020 Oct 8;383(15):1436-1446. doi: 10.1056/NEJMoa2024816.

183. Yau K., Dharia A., Alrowiyti I., Cherney D.Z.I. Prescribing SGLT2 Inhibitors in Patients With CKD: Expanding Indications and Practical Considerations. Kidney Int Rep. 2022 May 5;7(7):1463-1476. doi: 10.1016/j.ekir.2022.04.094.

184. Kanwal F., Shubrook J.H., Younossi Z. et al. Preparing for the NASH Epidemic: A Call to Action. Diabetes Care. 2021 Sep;44(9):2162-2172. doi: 10.2337/dci21-0020.

185. Cusi K., Isaacs S., Barb D. et al. American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings: Co-Sponsored by the American Association for the Study of Liver Diseases (AASLD). Endocr Pract. 2022 May;28(5):528-562. doi: 10.1016/j.eprac.2022.03.010.

186. Kanwal F., Shubrook J.H., Adams L.A. et al. Clinical Care Pathway for the Risk Stratification and Management of Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology. 2021 Nov;161(5):1657-1669. doi: 10.1053/j.gastro.2021.07.049.

187. The EMPA-KIDNEY Collaborative Group; Herrington W.G., Staplin N., Wanner C., Green J.B. et al. Empagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2023 Jan 12;388(2):117-127. doi: 10.1056/NEJMoa2204233.

188. Eriksson J.W., Lundkvist P., Jansson P.A. et al. Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: a double-blind randomised placebo-controlled study. Diabetologia. 2018 Sep;61(9):1923-1934. doi: 10.1007/s00125-018-4675-2.

189. Kuchay M.S., Krishan S., Mishra S.K. et al. Effect of Empagliflozin on Liver Fat in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial (E-LIFT Trial). Diabetes Care. 2018 Aug;41(8):1801-1808. doi: 10.2337/dc18-0165.

190. Shibuya T., Fushimi N., Kawai M., Yoshida Y., Hachiya H., Ito S., Kawai H., Ohashi N., Mori A. Luseogliflozin improves liver fat deposition compared to metformin in type 2 diabetes patients with non-alcoholic fatty liver disease: A prospective randomized controlled pilot study. Diabetes Obes Metab. 2018 Feb;20(2):438-442. doi: 10.1111/dom.13061.

191. Kahl S., Gancheva S., Straßburger K. et al. Empagliflozin Effectively Lowers Liver Fat Content in Well-Controlled Type 2 Diabetes: A Randomized, Double-Blind, Phase 4, Placebo-Controlled Trial. Diabetes Care. 2020 Feb;43(2):298-305. doi: 10.2337/dc19-0641.

192. Jin Z., Yuan Y., Zheng C., Liu S., Weng H. Effects of sodium-glucose co-transporter 2 inhibitors on liver fibrosis in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus: An updated meta-analysis of randomized controlled trials. J Diabetes Complications. 2023;37(8):108558. doi: 10.1016/j.jdiacomp.2023.108558.

193. Ong Lopez A.M.C., Pajimna J.A.T. Efficacy of sodium glucose cotransporter 2 inhibitors on hepatic fibrosis and steatosis in non-alcoholic fatty liver disease: an updated systematic review and meta-analysis. Sci Rep. 2024;14(1):2122. doi: 10.1038/s41598-024-52603-5.

194. Seko Y., Sumida Y., Tanaka S. et al. Effect of sodium glucose cotransporter 2 inhibitor on liver function tests in Japanese patients with non-alcoholic fatty liver disease and type 2 diabetes mellitus. Hepatol Res. 2017 Sep;47(10):1072-1078. doi: 10.1111/hepr.12834.

195. Choi D.H., Jung C.H., Mok J.O., Kim C.H., Kang S.K., Kim B.Y. Effect of Dapagliflozin on Alanine Aminotransferase Improvement in Type 2 Diabetes Mellitus with Non-alcoholic Fatty Liver Disease. Endocrinol Metab (Seoul). 2018 Sep;33(3):387-394. doi: 10.3803/EnM.2018.33.3.387.

196. Itani T., Ishihara T. Efficacy of canagliflozin against nonalcoholic fatty liver disease: a prospective cohort study. Obes Sci Pract. 2018 Aug 22;4(5):477-482. doi: 10.1002/osp4.294.

197. Sumida Y., Murotani K., Saito M., Tamasawa A., Osonoi Y., Yoneda M., Osonoi T. Effect of luseogliflozin on hepatic fat content in type 2 diabetes patients with non-alcoholic fatty liver disease: A prospective, single-arm trial (LEAD trial). Hepatol Res. 2019 Jan;49(1):64-71. doi: 10.1111/hepr.13236.

198. Wong C., Lee M.H., Yaow C.Y.L. et al. Glucagon-Like Peptide-1 Receptor Agonists for Non-Alcoholic Fatty Liver Disease in Type 2 Diabetes: A Meta-Analysis. Front Endocrinol (Lausanne). 2021;12:609110. doi: 10.3389/fendo.2021.609110.

199. Fan S., Shi X., Yao J., Zhong M., Feng P. The efficacy of glucagon-like peptide 1 receptor agonists in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis of randomized controlled trials. Rev Esp Enferm Dig. 2020;112(8):627-635.

200. Gomes D.A., Presume J., de Araújo Gonçalves P., Almeida M.S., Mendes M., Ferreira J. Association Between the Magnitude of Glycemic Control and Body Weight Loss With GLP-1 Receptor Agonists and Risk of Atherosclerotic Cardiovascular Disease: A Systematic Review and Meta-analyses of Randomized Diabetes Cardiovascular Outcomes Trials. Cardiovasc Drugs Ther. 2024. doi: 10.1007/s10557-024-07547-3.

201. Patel Chavez C., Cusi K, Kadiyala S. The Emerging Role of Glucagon-like Peptide-1 Receptor Agonists for the Management of NAFLD. J Clin Endocrinol Metab. 2022 Jan 1;107(1):29-38. doi: 10.1210/clinem/dgab578.

202. Yoshiji S., Minamino H., Tanaka D., Yamane S., Harada N., Inagaki N. Effects of glucagon-like peptide-1 receptor agonists on cardiovascular and renal outcomes: A meta-analysis and meta-regression analysis. Diabetes Obes Metab. 2022 Jun;24(6):1029-1037. doi: 10.1111/dom.14666.

203. Parab P., Chaudhary P., Mukhtar S. et al. Role of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Cardiovascular Risk Management in Patients With Type 2 Diabetes Mellitus: A Systematic Review. Cureus. 2023;15(9): e45487. doi: 10.7759/cureus.45487.

204. Banerjee M., Pal R., Mukhopadhyay S., Nair K. GLP-1 Receptor Agonists and Risk of Adverse Cerebrovascular Outcomes in Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. J Clin Endocrinol Metab. 2023;108(7):1806-1812. doi: 10.1210/clinem/dgad076.

205. Kristensen S.L., Rørth R., Jhund P.S. et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diabetes Endocrinol. 2019 Oct;7(10):776-785. doi: 10.1016/S2213-8587(19)30249-9.

206. Ferhatbegović L., Mršić D., Macić-Džanković A. The benefits of GLP1 receptors in cardiovascular diseases. Front Clin Diabetes Healthc. 2023 Dec 8;4:1293926. doi: 10.3389/fcdhc.2023.1293926.

207. Bethel M.A., Patel R.A., Merrill P., Lokhnygina Y., Buse J.B., Mentz R.J., Pagidipati N.J., Chan J.C., Gustavson S.M., Iqbal N., Maggioni A.P., Öhman P., Poulter N.R., Ramachandran A., Zinman B., Hernandez A.F., Holman R.R.; EXSCEL Study Group. Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis. Lancet Diabetes Endocrinol. 2018 Feb;6(2):105-113. doi: 10.1016/S2213-8587(17)30412-6.

208. Palmer S.C., Tendal B., Mustafa R.A. et al. Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials. BMJ. 2021;372: m4573. doi: 10.1136/bmj.m4573.

209. Greco E.V., Russo G., Giandalia A., Viazzi F., Pontremoli R., De Cosmo S. GLP-1 Receptor Agonists and Kidney Protection. Medicina (Kaunas). 2019;55(6): 233. doi: 10.3390/medicina55060233.

210. Marso S.P., Daniels G.H., Brown-Frandsen K. et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2016;375(4):311-322. doi: 10.1056/NEJMoa1603827.

211. Marso S.P., Bain S.C., Consoli A. et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2016;375(19):1834-1844. doi: 10.1056/NEJMoa1607141.

212. Gerstein H.C., Colhoun H.M., Dagenais G.R. et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019;394(10193):121-130. doi: 10.1016/S0140-6736(19)31149-3.

213. Mantovani A., Petracca G., Beatrice G., Csermely A., Lonardo A., Targher G. Glucagon-Like Peptide-1 Receptor Agonists for Treatment of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: An Updated Meta-Analysis of Randomized Controlled Trials. Metabolites. 2021 Jan 27;11(2):73. doi: 10.3390/metabo11020073.

214. Newsome P.N., Buchholtz K., Cusi K. et al. A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis. N Engl J Med. 2021;384(12):1113-1124. doi: 10.1056/NEJMoa2028395.

215. Аrmstrong M.J., Gaunt P., Aithal G.P. et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): A multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet. 2016;387:679-690. doi: 10.1016/s0140-6736(15)00803-x.

216. Zhu K., Kakkar R., Chahal D., Yoshida E.M., Hussaini T. Efficacy and safety of semaglutide in non-alcoholic fatty liver disease. World J Gastroenterol. 2023;29(37):5327-5338. doi: 10.3748/wjg.v29.i37.5327.

217. Bandyopadhyay S., Das S., Samajdar S.S., Joshi S.R. Role of semaglutide in the treatment of nonalcoholic fatty liver disease or non-alcoholic steatohepatitis: A systematic review and meta-analysis. Diabetes Metab Syndr. 2023;17(10):102849. doi: 10.1016/j.dsx.2023.102849.

218. Gu Y., Sun L., Zhang W. et al.Comparative efficacy of 5 sodium-glucose cotransporter protein-2 (SGLT-2) inhibitor and 4 glucagon-like peptide-1 (GLP-1) receptor agonist drugs in non-alcoholic fatty liver disease: A GRADE-assessed systematic review and network meta-analysis of randomized controlled trials. Front Pharmacol. 2023;14:1102792. doi: 10.3389/fphar.2023.1102792.

219. Zafar Y., Rashid A.M., Siddiqi A.K. et al. Effect of novel glucose lowering agents on non-alcoholic fatty liver disease: A systematic review and meta-analysis. Clin Res Hepatol Gastroenterol. 2022 Aug-Sep;46(7):101970. doi: 10.1016/j.clinre.2022.101970.

220. Armstrong M.J., Okanoue T., Sundby Palle M., Sejling A.S., Tawfik M., Roden M. Similar weight loss with semaglutide regardless of diabetes and cardiometabolic risk parameters in individuals with metabolic dysfunction-associated steatotic liver disease: Post hoc analysis of three randomised controlled trials. Diabetes Obes Metab. 2024 Nov 28. doi: 10.1111/dom.16065.

221. Ivashkin V.T., Mayev I.V., Shulpekova Yu.O., Baranskaya Ye.K., Okhlobystin A.V., Trukhmanov A.S., Lapina T.L., Sheptulin A.A. Diagnostics and treatment of biliary dyskinesia: clinical guidelines of the Russian gastroenterological Association.Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2018;28(3):63-80. (In Russ.) doi: 10.22416/1382-4376-2018-28-3-63-80.@@ Ивашкин В.Т., Маев И.В., Шульпекова Ю.О., Баранская Е.К., Охлобыстин А.В., Трухманов А.С., Лапина Т.Л., Шептулин А.А. Клинические рекомендации Российской гастроэнтерологической ассоциации по диагностике и лечению дискинезии желчевыводящих путей. Рос журн гастроэнтерол гепатол колопроктол 2018; 28(3):63-80. doi: 10.22416/1382-4376-2018-28-3-63-80.

222. Stanghellini V., Chan F.K., Hasler W.L. et al. Gastroduodenal Disorders. Gastroenterology. 2016 May;150(6):1380-92. doi: 10.1053/j.gastro.2016.02.011.

223. Martsevich S. Yu., Kutishenko N.P., Drozdova L. Yu., Lerman O.V., Nevzorova V.A., Reznik I.I., Shavkuta G.V., Yahontov D.A. Study of ursodeoxycholic acid influence on efficacy and safety of statin therapy in patients with diseases of the liver, gall bladder and/or biliary tract (the rakurs study). Rational Pharmacotherapy in Cardiology. 2014;10(2):147-152. (In Russ.) doi: 1819-6446-2014-10-2-147-152.@@ Марцевич С.Ю., Кутишенко Н.П., Дроздова Л.Ю., Лерман О.В., Невзорова В.А., Резник И.И., Шавкута Г.В., Яхонтов Д.А., рабочая группа исследования РАКУРС. Изучение влияния урсодезоксихолевой кислоты на эффективность и безопасность терапии статинами у больных с заболеваниями печени, желчного пузыря и (или) желчевыводящих путей (исследование РАКУРС). Рациональная Фармакотерапия в Кардиологии. 2014; 10 (2), 147-152. doi: 1819-6446-2014-10-2-147-152.

224. Cabezas Gelabert R. Efecto del ácido ursodesoxicólico combinado con estatinas para el tratamiento de la hipercolesterolemia: ensayo clínico prospectivo [Effect of ursodeoxycholic acid combined with statins in hypercholesterolemia treatment: a prospective clinical trial]. Rev Clin Esp. 2004 Dec;204(12):632-5. Spanish. doi: 10.1016/s0014-2565(04)71566-0.

225. Drapkina O. M., Bueverova E.L. Ursodeoxycholic acid: a therapeutic niche in the practice of an internist. Therapeutic archive. 2015;87(4):84-90. (in Russ.)@@ Драпкина О.М., Буеверова Е.Л. Урсодезоксихолевая кислота: терапевтическая ниша в практике интерниста. Терапевтический архив. - 2015. - Т. 87. - № 4. - С. 84-90.

226. Seo S.H., Lee D.H., Lee Y.S. et al. Co-administration of ursodeoxycholic acid with rosuvastatin/ezetimibe in a non-alcoholic fatty liver disease model. Gastroenterol Rep (Oxf). 2022 Aug 13;10: goac037. doi: 10.1093/gastro/goac037.

227. Suchkova E.V., Lukashevich A.P. Correction of lipid metabolism disorders with atorvastatin in combination with UDCA in NAFLD. Experimental and Clinical Gastroenterology. 2020;(9):40-44. (In Russ.) doi: 10.31146/1682-8658-ecg-181-9-40-44.@@ Сучкова Е.В., Лукашевич А.П. Коррекция нарушений липидного обмена аторвастатином к комбинации с УДХК при НАЖБП. Экспериментальная и клиническая гастроэнтерология. 2020;(9):40-44. doi: 10.31146/1682-8658-ecg-181-9-40-44.

228. Naginskaya M., Martsevich S., Kutishenko N., Balashov I., Lerman O. P0624 Ursodeoxycholic acid influence on efficacy and safety of statin therapy in patients with high risk of cardiovascular events and nonalcoholic fatty liver disease: the RACURS study (post-hoc analysis). United European Gastroenterol J. 2015;3(Suppl. 5): P0624. doi: 10.1177/2050640615601623.

229. Simental-Mendía L.E., Simental-Mendía M., Sánchez-García A. et al. Impact of ursodeoxycholic acid on circulating lipid concentrations: a systematic review and meta-analysis of randomized placebo-controlled trials. Lipids Health Dis. 2019;18(1):88. Published 2019 Apr 6. doi:10.1186/s12944-019-1041-4.

230. Trauner M., Claudel T., Fickert P., Moustafa T., Wagner M. Bile acids as regulators of hepatic lipid and glucose metabolism. Dig Dis. 2010;28(1):220-4. doi: 10.1159/000282091.

231. Shipovskaya A.A., Kurbatova I.V., Dudanova O.P. Pleiotropic e ects of ursodeoxycholic acid in patients with non-alcoholic steatohepatitis with impaired glycemic control. Experimental and Clinical Gastroenterology. 2020;183(11):34-38. (In Russ.) doi: 10.31146/1682-8658-ecg-183-11-34-38.@@ Шиповская А.А., Курбатова И.В., Дуданова О.П. Плейотропные эффекты урсодезоксихолевой кислоты у пациентов неалкогольным стеатогепатитом с нарушенным гликемическим контролем. Экспериментальная и клиническая гастроэнтерология. 2020;183(11): 34-38. doi: 10.31146/1682-8658-ecg-183-11-34-38.

232. Sánchez-García A., Sahebkar A., Simental-Mendía M., Simental-Mendía L.E. Effect of ursodeoxycholic acid on glycemic markers: A systematic review and meta-analysis of clinical trials. Pharmacol Res. 2018;135:144-149. doi: 10.1016/j.phrs.2018.08.008.

233. Elhini S.H., Wahsh E.A., Elberry A.A. et al. The Impact of an SGLT2 Inhibitor versus Ursodeoxycholic Acid on Liver Steatosis in Diabetic Patients. Pharmaceuticals (Basel). 2022;15(12):1516. doi: 10.3390/ph15121516.

234. Dajani A.I., Popovic B. Essential phospholipids for nonalcoholic fatty liver disease associated with metabolic syndrome: A systematic review and network meta-analysis. World J Clin Cases. 2020 Nov 6;8(21):5235-5249. doi: 10.12998/wjcc.v8.i21.5235.

235. Maev I.V., Samsonov A.A., Palgova L.K. et al. Effectiveness of phosphatidylcholine in alleviating steatosis in patients with non-alcoholic fatty liver disease and cardiometabolic comorbidities (MANPOWER study) BMJ Open Gastroenterology. 2020;7: e000341.

236. Dajani A.I., Abuhammour A. Agents for the treatment of fatty liver disease: focus on essential phospholipids. Drugs Ther Perspect. 2021;(37):249-264. doi: 10.1007/s40267-021-00838-x.

237. Raikhelson K.L., Kondrashina E.A. Àdåmethionine in the treatment of fatigue in liver diseases: a systematic review. Therapeutic Archive. 2019; 91 (2): 134-142. doi: 10.26442/00403660.2019.02.000130.@@ Райхельсон К.Л., Кондрашина Э.Л. Адеметионин в лечении повышенной утомляемости/слабости при заболеваниях печени: систематический обзор. Терапевтический архив. 2019;91(2):134-142. doi: 10.26442/00403660.2019.02.000130.

238. Saigal S., Kapoor D., Roy D.S. Ademetionine in patients with liver disease: a reweviw.Int J Res Med Sci. 2019;7(6):2482-93.

239. Polyakova O.A., Kozgunova L.D., Ostroumova O.D. Metabolically associated fatty liver disease: the role of ademetionine. Farmateka. 2023;30(1/2):54-62. doi: 10.18565/pharmateca.2023.1-2.54-62.@@ Полякова О.А., Козгунова Л.Д., Остроумова О.Д. Метаболически ассоциированная жировая болезнь печени: роль адеметионина. Фарматека. - 2023. - Т. 30. - № 1/2. - C. 54-62. doi: 10.18565/pharmateca.2023.1-2.54-62.

240. Virukalpattigopalratnam M.P., Singh T., Ravishankar A.C. Heptral (ademetionine) in patients with intrahepatic cholestasis in chronic liver disease due to non-alcoholic liver disease: results of a multicentre observational study in India. J Indian Med Assoc. 2013 Dec;111(12):856-9. PMID: 25154164.

241. Noureddin M., Sander-Struckmeier S., Mato J.M. Early treatment efficacy of S-adenosylmethionine in patients with intrahepatic cholestasis: A systematic review. World J Hepatol. 2020 Feb 27;12(2):46-63. doi: 10.4254/wjh.v12.i2.46.

242. Baranovsky A. Yu., Raikhelson K.L., Marchenko N.V. Use of S-adenosylmethionine (Geptral®) in the treatment of patients with non-alcoholic steatohepatitis. Clinical Perspectives of Gastroenterology, Hepatology. 2010;9(1):3-10.@@ Барановский А.Ю., Райхельсон К.Л., Марченко Н.В. Применение S-аденозилметионина (Гептрала®) в терапии больных неалкогольным стеатогепатитом. Клинические перспективы гастроэнтерологии, гепатологии. 2010;9(1):3-10.

243. American Association for the Study of Liver Diseases, European Association for the Study of the Liver. Hepatic encephalopathy in chronic liver disease: 2014 practice guideline by the European Association for the Study of the Liver and the American Association for the Study of Liver Diseases. J. Hepatol. 2014;61(3):642-659.

244. Butterworth R.F., Kircheis G., Hilger N., McPhail M.J.W. Effect of L-ornithine L-aspartate for the treatment of hepatic encephalopathy and hyperammonemia in cirrhosis: systematic review and meta-analysis of ran- domized controlled trials. J Clin Exp Hepatol. 2018. doi: 10.1016/j.jceh.2018.05.004.

245. Petrova E. M., Cheraneva V.A., Grachev V.G. Hepatogenic weakness as a clinical marker of hyperammonemia and of the effectiveness of its correction in patients with pre-cirrhotic stages of non-alcoholic fatty liver disease. Lvrach.ru. 2020; 8:48-53. (in Russ.)@@ Петрова Э.М., Черанева В.А., Грачев В.Г. Гепатогенная слабость как клинический маркер гипераммониемии и эффективность ее коррекции у пациентов с доцирротическими стадиями неалкогольной жировой болезни печени Лечащий врач. 2020; 8:48-53.

246. Statsenko M.E., Turkina S.V., Gorbacheva E.E. et al. Influence of taurin at the degree of internal obesity and severity of visceral fat dysfunction in patients with non-alcoholic fatty liver disease. Consilium Medicum. 2019; 21 (12): 128-133. (in Russ.) doi: 10.26442/20751753.2019.12.190666.@@ Стаценко М.Е., Туркина С.В., Горбачева Е.Е. и др. Влияние таурина на уровень висцерального ожирения и выраженность дисфункции висцерального жира у пациентов с неалкогольной жировой болезнью печени. Consilium Medicum. 2019; 21 (12):128-133. doi: 10.26442/20751753.2019.12.190666

247. Guan L., Miao P. The effects of taurine supplementation on obesity, blood pressure and lipid profile: A meta-analysis of randomized controlled trials. Eur J Pharmacol. 2020.885. P. 173533. doi: 10.1016/j.ejphar.2020.17353.

248. Sun Q., Wang, B., Li Y. et al. Taurine supplementation lowers blood pressure and improves vascular function in prehypertension: randomized, double-blind, placebo controlled study. Hypertension. 2016;(67):541-549.

249. Statsenkо M.E., Turkina S.V., Shilina N.N. Liver damage in patients with ischemic chronic heart and type 2 diabetes - a treacherous tandem: possible additional organoprotective therapy. Consilium Medicum. 2016; 18 (5):103-109. (in Russ.)@@ Стаценко М.Е., Туркина С.В., Шилина Н.Н. Поражение печени у больных с хронической сердечной недостаточностью ишемического генеза и сахарным диабетом типа 2 - коварный тандем: возможности дополнительной органопротективной терапии. Consilium Medicum. 2016;18(5):103-109.

250. Tao X., Zhang Z., Yang Z., Rao B. The effects of taurine supplementation on diabetes mellitus in humans: A systematic review and meta-analysis. Food Chem (Oxf). 2022.4. P. 100106. doi: 10.1016/j.fochms.2022.100106.

251. Tzang C.C., Lin W.C., Lin L.H., Lin T.Y., Chang K.V., Wu W.T., Özçakar L. Insights into the cardiovascular benefits of taurine: a systematic review and meta-analysis. Nutr J. 2024 Aug 15;23(1):93. doi: 10.1186/s12937-024-00995-5.

252. Tzang C.C., Chi L.Y., Lin L.H. et al. Taurine reduces the risk for metabolic syndrome: a systematic review and meta-analysis of randomized controlled trials. Nutr. Diabetes. 2024;14:29. doi: 10.1038/s41387-024-00289-z.

253. Kadin D.V., Chumak B.A., Filippov A.E., Shustov S.B. Thiotriazolin in the complex therapy of stable angina of effort II-III functional class. Cardiology. 2015;8:72-81. (in Russ.)@@ Кадин Д.В., Чумак Б.А., Филиппов А.Е., Шустов С.Б. Тиотриазолин в комплексной терапии стабильной стенокардии напряжения II-III функционального класса. Кардиология.-2015.-№ 8.-С.72-81.

254. Kinoschenko E.I., Nikonov V.V., Belaya I.E., Kolomiets V.I.Integrated approach to the treatment of myocardial infarction combined with non-alcoholic fatty liver disease. Emergency Medicine. 2017;1(80):47-60. (in Russ.)@@ Киношенко Е.И., Никонов В.В., Белая И.Е., Коломиец В.И. Комплексный подход к терапии инфаркта миокарда, сочетанного с неалкогольной жировой болезнью печени. Медицина неотложных состояний. 2017;1(80):47-60.

255. Savchenko S.A., Filippov A.E. [Proceedings of the symposium «Thiotriazolin: cardioprotection from the standpoint of evidence-based medicine» within the framework of the Russian National Congress of Cardiologists].Russian Medical Journal. 2017;(27):1638-1643. (In Russ.)@@ Савченко С.А., Филиппов А.Е. Материалы симпозиума «Тиотриазолин: кардиопротекция с позиции доказательной медицины» в рамках Российского национального конгресса кардиологов. Русский медицинский журнал. 2017. № 27. C. 1638-1643.

256. Khokhlachyova N.А., Glazyrina N.N. Cholelithiasis: chances to avoid cholecystectomy. Medical alphabet. 2019;3(20):5-10. (In Russ.) doi: 10.33667/2078-5631-2019-3-20(395)-5-10.@@ Хохлачева Н.А., Глазырина Н.Н. Желчнокаменная болезнь: есть ли шанс избежать холецистэктомии? Медицинский алфавит. 2019;3(20):5-10. doi: 10.33667/2078-5631-2019-3-20(395)-5-10.

257. Maev I.V., Dicheva D.T., Buragina T.A. Diagnostics and treatment of biliary sludge in patients with peptic ulcer. RZhGGK. 2007;4:68-72. (in Russ.)@@ Маев И.В., Дичева Д.Т., Бурагина Т.А. Диагностика и лечение билиарного сладжа у больных язвенной болезнью РЖГГК. 2007. № 4, 68-72.

258. Mekhtiev S.N., Mekhtieva O.A. Functional disorders of the gallbladder in the practice of the therapist. Consilium Medicum. 2017; 19 (8.1. Gastroenterology): 35-41. (in Russ.)@@ Мехтиев С.Н., Мехтиева О.А. Функциональные расстройства желчного пузыря в практике терапевта. Consilium Medicum. 2017; 19 (8.1. Гастроэнтерология): 35-41.

259. Seliverstov P., Sitkin S., Radchenko V. et al.Combined lipid-lowering therapy in patients with nonalcoholic fatty liver disease. Vrach. 2018; 29 (11):36-43. (in Russ.) doi: 10.29296/25877305-2018-11-07.@@ Селиверстов П., Ситкин С., Радченко В. и др. Комбинированная гиполипидемическая терапия у пациентов с неалкогольной жировой болезнью печени. Врач. - 2018; 29 (11): 36-43. doi: 10.29296/25877305-2018-11-07.

260. Pittler M.H., Thompson C.J., and Ernst E. “Artichoke leaf extract for treating hypercholesterolaemia,” The Cochrane Database of Systematic Reviews, no. 4, Article ID CD003335, 2009.

261. Bundy R., Walker A.F., Middleton R.W., Wallis C., Simpson H.C. Artichoke leaf extract (Cynara scolymus) reduces plasma cholesterol in otherwise healthy hypercholesterolemic adults: a randomized, double blind placebo controlled trial. Phytomedicine. 2008 Sep;15(9):668-75. doi: 10.1016/j.phymed.2008.03.001.

262. Ji X., Shi S., Liu B., Shan M., Tang D., Zhang W., Zhang Y., Zhang L., Zhang H., Lu C., Wang Y. Bioactive compounds from herbal medicines to manage dyslipidemia. Biomed Pharmacother. 2019 Oct;118:109338. doi: 10.1016/j.biopha.2019.109338.

263. Santos H.O., Bueno A.A., Mota J.F. The effect of artichoke on lipid profile: A review of possible mechanisms of action. Pharmacol Res. 2018 Nov;137:170-178. doi: 10.1016/j.phrs.2018.10.007.

264. Loomba R., Lutchman G., Kleiner D.E. et al. Clinical trial: pilot study of metformin for the treatment of non-alcoholic steatohepatitis. Aliment Pharmacol Ther. 2009 Jan;29(2):172-82. doi: 10.1111/j.1365-2036.2008.03869.x.

265. Huang Y., Wang X., Yan C., Li C., Zhang L., Zhang L., Liang E., Liu T., Mao J. Effect of metformin on nonalcoholic fatty liver based on meta-analysis and network pharmacology. Medicine (Baltimore). 2022 Oct 28;101(43): e31437. doi: 10.1097/ MD.0000000000031437.

266. Hu H., Wang J., Li X., Shen L., Shi D., Meng J. The Effect of Metformin on Aminotransferase Levels, Metabolic Parameters and Body Mass Index in Nonalcoholic Fatty Liver Disease Patients: A Metaanalysis. Curr Pharm Des. 2021;27(29):3235-3243. doi: 10.2174/1381612827666210315144821.

267. Nair S., Diehl A.M., Wiseman M., Farr G.H. Jr., Perrillo R.P. Metformin in the treatment of non-alcoholic steatohepatitis: a pilot open label trial. Aliment Pharmacol Ther. 2004 Jul 1;20(1):23-8. doi: 10.1111/j.1365-2036.2004.02025.x.

268. Mazhar I.J., Yasir M., Sarfraz S. et al. Vitamin E and Pioglitazone: A Comprehensive Systematic Review of Their Efficacy in Non-alcoholic Fatty Liver Disease. Cureus. 2023;15(8): e43635. doi: 10.7759/cureus.43635.

269. Rinella M.E., Neuschwander-Tetri B.A., Siddiqui M.S. et al. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023 May 1;77(5):1797-1835. doi: 10.1097/HEP.0000000000000323.

270. Bril F., Kalavalapalli S., Clark V.C. et al. Response to pioglitazone in patients with nonalcoholic steatohepatitis with vs without type 2 diabetes. Clin Gastroenterol Hepatol. 2018;16:558-566.e2.

271. Musso G., Cassader M., Paschetta E., Gambino R. Thiazolidinediones and advanced liver fibrosis in nonalcoholic steatohepatitis: a meta-analysis. JAMA Intern Med 2017;177:633-640.

272. Ndakotsu A., Vivekanandan G. The Role of Thiazolidinediones in the Amelioration of Nonalcoholic Fatty Liver Disease: A Systematic Review. Cureus. 2022;14(5): e25380. doi: 10.7759/cureus.25380.

273. Xu X., Poulsen K.L., Wu L., Liu S., Miyata T., Song Q., Wei Q., Zhao C., Lin C., Yang J. Targeted therapeutics and novel signaling pathways in non-alcohol-associated fatty liver/steatohepatitis (NAFL/NASH). Signal Transduct Target Ther. 2022 Aug 13;7(1):287. doi: 10.1038/s41392-022-01119-3.

274. Bessone F., Razori M.V., Roma M.G. Molecular pathways of nonalcoholic fatty liver disease development and progression. Cell Mol Life Sci. 2019 Jan;76(1):99-128. doi: 10.1007/s00018-018-2947-0.

275. Gautheron J., Gores G.J., Rodrigues C.M.P. Lytic cell death in metabolic liver disease. J Hepatol. 2020 Aug;73(2):394-408. doi: 10.1016/j.jhep.2020.04.001.

276. Shojaie L., Iorga A., Dara L. Cell Death in Liver Diseases: A Review.Int J Mol Sci. 2020 Dec 18;21(24):9682. doi: 10.3390/ijms21249682.

277. Barreyro F.J., Holod S., Finocchietto P.V. et al. The pan-caspase inhibitor Emricasan (IDN-6556) decreases liver injury and fibrosis in a murine model of non-alcoholic steatohepatitis. Liver Int. 2015 Mar;35(3):953-66. doi: 10.1111/liv.12570.

278. Frenette C.T., Morelli G., Shiffman M.L. et al. Emricasan Improves Liver Function in Patients With Cirrhosis and High Model for End-Stage Liver Disease Scores Compared With Placebo. Clin Gastroenterol Hepatol. 2019 Mar;17(4):774-783.e4. doi: 10.1016/j.cgh.2018.06.012.

279. Harrison S.A., Goodman Z., Jabbar A. et al. A randomized, placebo-controlled trial of emricasan in patients with NASH and F1-F3 fibrosis. J Hepatol. 2020 May;72(5):816-827. doi: 10.1016/j.jhep.2019.11.024.

280. Ströbel S., Kostadinova R., Fiaschetti-Egli K. et al. A 3D primary human cell-based in vitro model of non-alcoholic steatohepatitis for efficacy testing of clinical drug candidates. Sci Rep. 2021 Nov 23;11(1):22765. doi: 10.1038/s41598-021-01951-7.

281. Harrison S.A., Wong V.W., Okanoue T. et al.; STELLAR-3; STELLAR-4 Investigators. Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials. J Hepatol. 2020 Jul;73(1):26-39. doi: 10.1016/j.jhep.2020.02.027.

282. Parthasarathy G., Malhi H. Macrophage Heterogeneity in NASH: More Than Just Nomenclature. Hepatology. 2021 Jul;74(1):515-518. doi: 10.1002/hep.31790.

283. Lefebvre E., Moyle G., Reshef R. et al. Antifibrotic Effects of the Dual CCR2/CCR5 Antagonist Cenicriviroc in Animal Models of Liver and Kidney Fibrosis. PLoS One. 2016 Jun 27;11(6): e0158156. doi: 10.1371/journal.pone.0158156.

284. Friedman S., Sanyal A., Goodman Z., Lefebvre E., Gottwald M., Fischer L., Ratziu V. Efficacy and safety study of cenicriviroc for the treatment of non-alcoholic steatohepatitis in adult subjects with liver fibrosis: CENTAUR Phase 2b study design. Contemp Clin Trials. 2016 Mar;47:356-65. doi: 10.1016/j.cct.2016.02.012.

285. Ratziu V., Sanyal A., Harrison S.A. et al. Cenicriviroc Treatment for Adults With Nonalcoholic Steatohepatitis and Fibrosis: Final Analysis of the Phase 2b CENTAUR Study. Hepatology. 2020 Sep;72(3):892-905. doi: 10.1002/hep.31108.

286. Meng F., Wang K., Aoyama T. et al.Interleukin-17 signaling in inflammatory, Kupffer cells, and hepatic stellate cells exacerbates liver fibrosis in mice. Gastroenterology. 2012 Sep;143(3):765-776.e3. doi: 10.1053/j.gastro.2012.05.049.

287. Dibra D., Xia X., Mitra A., Cutrera J.J., Lozano G., Li S. Mutant p53 in concert with an interleukin-27 receptor alpha deficiency causes spontaneous liver inflammation, fibrosis, and steatosis in mice. Hepatology. 2016 Mar;63(3):1000-12. doi: 10.1002/hep.28379.

288. Widjaja A.A., Singh B.K., Adami E. et al. Inhibiting Interleukin 11 Signaling Reduces Hepatocyte Death and Liver Fibrosis, Inflammation, and Steatosis in Mouse Models of Nonalcoholic Steatohepatitis. Gastroenterology. 2019 Sep;157(3):777-792.e14. doi: 10.1053/j.gastro.2019.05.002.

289. Ghanbari M., Momen Maragheh S., Aghazadeh A. et al.Interleukin-1 in obesity-related low-grade inflammation: From molecular mechanisms to therapeutic strategies.Int Immunopharmacol. 2021 Jul;96:107765. doi: 10.1016/j.intimp.2021.107765.

290. Chalasani N., Abdelmalek M.F., Garcia-Tsao G. et al; Belapectin (GR-MD-02) Study Investigators. Effects of Belapectin, an Inhibitor of Galectin-3, in Patients With Nonalcoholic Steatohepatitis With Cirrhosis and Portal Hypertension. Gastroenterology. 2020 Apr;158(5):1334-1345.e5. doi: 10.1053/j.gastro.2019.11.296.

291. Al Attar A., Antaramian A., Noureddin M. Review of galectin-3 inhibitors in the treatment of nonalcoholic steatohepatitis. Expert Rev Clin Pharmacol. 2021 Apr;14(4):457-464. doi: 10.1080/17512433.2021.1894127.

292. Lazebnik L.B., Turkina S.V. Enterohepatocentrism as the basis of human psychosomatic pathology. Experimental and Clinical Gastroenterology. 2023;(8):9-23. (In Russ.) doi: 10.31146/1682-8658-ecg-216-8-9-23.@@ Лазебник Л.Б., Туркина С.В. Энтерогепатоцентризм как основа психосоматической патологии человека. Экспериментальная и клиническая гастроэнтерология. 2023;(8):9-23. doi: 10.31146/1682-8658-ecg-216-8-9-23.

293. Wong V.W., Won G.L., Chim A.M., Chu W.C., Yeung D.K., Li K.C., Chan H.L. Treatment of nonalcoholic steatohepatitis with probiotics. A proof-of-concept study. Ann Hepatol. 2013 Mar-Apr;12(2):256-62. PMID: 23396737.

294. Zhou D., Pan Q., Shen F., Cao H.X., Ding W.J., Chen Y.W., Fan J.G. Total fecal microbiota transplantation alleviates high-fat diet-induced steatohepatitis in mice via beneficial regulation of gut microbiota. Sci Rep. 2017 May 8;7(1):1529. doi: 10.1038/s41598-017-01751-y.

295. Mohamad Nor M.H., Ayob N., Mokhtar N.M. et al. The Effect of Probiotics (MCP® BCMC® Strains) on Hepatic Steatosis, Small Intestinal Mucosal Immune Function, and Intestinal Barrier in Patients with Non-Alcoholic Fatty Liver Disease. Nutrients. 2021 Sep 14;13(9):3192. doi: 10.3390/nu13093192.

296. Samanta J., Dhar J., Facciorusso A. Reply. Clin Gastroenterol Hepatol. 2024 Nov;22(11):2350-2351. doi: 10.1016/j.cgh.2024.04.028.

297. Seyedi A. et al. Impact of bariatric surgery on liver fibrosis indices among type 2 diabetes patients in a national cohort. Scientific Reports. 2025;15(1):1235.

298. Chen V.L., Morgan T.R., Rotman Y., Patton H.M., Cusi K., Kanwal F., Kim W.R. Resmetirom therapy for metabolic dysfunction-associated steatotic liver disease: October 2024 updates to AASLD Practice Guidance. Hepatology. 2025;81(1):312-320. doi: 10.1097/HEP.0000000000001112.

299. Stokes C.S., Gluud L.L., Casper M., Lammert F. Ursodeoxycholic acid and diets higher in fat prevent gallbladder stones during weight loss: a meta-analysis of randomized controlled trials. Clin Gastroenterol Hepatol. 2014;12(7):1090-1100.e2. doi: 10.1016/j.cgh.2013.11.031.

300. Fearon N.M., Kearns E.C., Kennedy C.A., Conneely J.B., Heneghan H.M. The impact of ursodeoxycholic acid on gallstone disease after bariatric surgery: a meta-analysis of randomized control trials. Surg Obes Relat Dis. 2022 Jan;18(1):77-84. doi: 10.1016/j.soard.2021.10.004.

301. Mulliri A., Menahem B., Alves A., Dupont B. Ursodeoxycholic acid for the prevention of gallstones and subsequent cholecystectomy after bariatric surgery: a meta-analysis of randomized controlled trials. J Gastroenterol. 2022 Aug;57(8):529-539. doi: 10.1007/s00535-022-01886-4.

302. Alexis López Alonso, Hector Gabriel Zamora Valenzuela The Role of Ursodeoxycholic Acid After Bariatric Surgery.International Journal Of Health & Medical Research. 2024 July; 03(07):510-514. doi: 10.58806/ijhmr.2024.v3i07n16.

303. Sharma A., Shanti H., Nageswaran H., Best L.M.J., Patel A.G. Role of Ursodeoxycholic Acid in the Prevention of Gallstones Formation in Bariatric Patients-a Systematic Review and Meta-Analysis of Randomised Trials. Obes Surg. 2023 Oct 23. doi: 10.1007/s11695-023-06893-9.

304. Machado F.H.F., Castro Filho H.F., Babadopulos R.F.A.L., Rocha H.A.L., Rocha J.L.C., Moraes Filho M.O. Ursodeoxycholic acid in the prevention of gallstones in patients subjected to Roux-en-Y gastric bypass1. Acta Cir Bras. 2019 Feb 14;34(1): e20190010000009. doi: 10.1590/s0102-865020190010000009. Erratum in: Acta Cir Bras. 2019 May 6;34(4): e2019004ERRATA. doi: 10.1590/s0102-865020190010000009erratum.

305. Bhasker A.G., Prasad A., Shah S., Parmar C., Contributors O.G.B.C. MGB-OAGB International Club-Results of a Modified Delphi Consensus on Controversies in OAGB. Obes Surg. 2024 Dec;34(12):4541-4554. doi: 10.1007/s11695-024-07563-0.

306. Bischoff S.C., Barazzoni R., Busetto L. et al. European guideline on obesity care in patients with gastrointestinal and liver diseases - Joint European Society for Clinical Nutrition and Metabolism / United European Gastroenterology guideline. United European Gastroenterol J. 2022 Aug 12. doi: 10.1002/ueg2.12280.